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Perfect as the wing of  a bird may be, it will never enable the bird to fly if  unsupported by the air. 
Facts are the air of  science. Without them a man of  science can never rise.
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One-third of  patients with type 1 diabetes develop diabetic complications, such as diabetic nephro-
pathy. The diabetic complications are related to a high mortality from cardiovascular disease, impose 
a great burden on the health care system, and reduce the health-related quality of  life of  patients.
Aims
This thesis assessed, whether parental risk factors identify subjects at a greater risk of  developing 
diabetic complications. Another aim was to evaluate the impact of  a parental history of  type 2 dia-
betes on patients with type 1 diabetes. A third aim was to assess the role of  the metabolic syndrome 
in patients with type 1 diabetes, both its presence and its predictive value with respect to complica-
tions. 
Subjects and methods
This study is part of  the ongoing nationwide Finnish Diabetic Nephropathy (FinnDiane) Study. 
The study was initiated in 1997, and, thus far, 4,800 adult patients with type 1 diabetes have been 
recruited. Since 2004, follow-up data have also been collected in parallel to the recruitment of  new 
patients. Studies I to III have a cross-sectional design, whereas Study IV has a prospective design. 
Information on parents was obtained from the patients with type 1 diabetes by a questionnaire.
Results
Clustering of  parental hypertension, cardiovascular disease, and diabetes (type 1 and type 2) was 
associated with diabetic nephropathy in patients with type 1 diabetes, as was paternal mortality. 
A parental history of  type 2 diabetes was associated with a later onset of  type 1 diabetes, a higher 
prevalence of  the metabolic syndrome, and a metabolic profile related to insulin resistance, despite 
no difference in the distribution of  human leukocyte antigen genotypes or the presence of  diabetic 
complications. A maternal history of  type 2 diabetes, seemed to contribute to a worse metabolic 
profile in the patients with type 1 diabetes than a paternal history. The metabolic syndrome was a 
frequent finding in patients with type 1 diabetes, observed in 38% of  males and 40% of  females. 
The prevalence increased with worsening of  the glycemic control and more severe renal disease. 
The metabolic syndrome was associated with a 3.75-fold odds ratio for diabetic nephropathy, and 
all of  the components of  the syndrome were independently associated with diabetic nephropathy. 
The metabolic syndrome, independent of  diabetic nephropathy, increased the risk of  cardiovascular 
events and cardiovascular and diabetes-related mortality over a 5.5-year follow-up. With respect to 
progression of  diabetic nephropathy, the role of  the metabolic syndrome was less clear, playing a 
strong role only in the progression from macroalbuminuria to end-stage renal disease.
Conclusions
Familial factors and the metabolic syndrome play an important role in patients with type 1 diabetes. 
Assessment of  these factors is an easily applicable tool in clinical practice to identify patients at a 





Diabetes currently affects more than 240 mil-
lion people worldwide. If  the level of  obesity 
were to remain constant, by the year 2025, this 
number will reach 380 million, with the grea-
test increase expected in developing countries 
[1]. Such a dramatic increase is mainly due to 
environmental and behavioral factors such as a 
sedentary lifestyle, overly rich nutrition, and ob-
esity. The majority of  individuals with diabetes 
have type 2 diabetes, although the incidence of  
type 1 diabetes is also increasing in parallel with 
the changes in human behavior and lifestyle 
[2,3]. The health implications of  this epidemic 
are of  unrivalled proportions in terms of  mor-
bidity, mortality, and resources directed towards 
managing the complications of  diabetes [4]. 
Many people with diabetes become blind, re-
quire amputations, or develop progressive renal 
impairment, and most of  them will eventually 
succumb to cardiovascular complications [5]. 
The increase in the prevalence of  diabetes has 
also led to an increase in diabetic complications. 
The number of  patients in renal replacement 
therapy (dialysis or renal transplant) is expected 
to rise worldwide to 2 million by the year 2010 
[6]. 
Diabetic nephropathy affects one-third of  pa-
tients with type 1 diabetes, and there is an in-
cidence peak after 15 to 20 years of  diabetes 
[7], as well as familial clustering of  nephropathy 
[8], suggesting a genetic predisposition. One ap-
proach in the search for genes behind diabetic 
nephropathy is to identify familial risk factors. 
Several studies have been performed, and the 
familial traits investigated include hypertensi-
on, cardiovascular disease, type 2 diabetes, early 
mortality, and factors related to insulin resistan-
ce. The results of  these often underpowered 
studies have been contradictory, and none of  
these have examined the combined effect of  
these traits or the separate impact of  maternal 
and paternal history of  the traits. 
Patients with type 1 diabetes have a higher pre-
valence of  type 2 diabetes in their families than 
in the general population [9]. With the rapidly 
growing epidemic of  type 2 diabetes, a family 
history of  type 2 diabetes is anticipated to be-
come more frequent in patients with type 1 dia-
betes in the future. It is noteworthy that a family 
history of  type 2 diabetes is strongly associated 
with a genetic predisposition to type 2 diabetes 
[10]. A family history of  type 2 diabetes is also 
associated with insulin resistance and the me-
tabolic syndrome in offspring without diabetes 
[11,12]. Data on the consequences of  a family 
history of  type 2 diabetes for the patients with 
type 1 diabetes are, however, limited.
Patients with type 1 diabetes have an increased 
risk of  cardiovascular morbidity and mortality, 
and this risk is to a large extent explained by 
the presence of  diabetic nephropathy, but even 
patients without diabetic nephropathy have a 
4-fold increased risk compared with subjects 
without diabetes [5]. The metabolic syndrome 
is an important risk factor for cardiovascular 
disease and even for chronic renal disease in 
the general population and in patients with type 
2 diabetes [13,14]. The metabolic syndrome 
comprises a cluster of  cardiovascular risk fac-
tors, including insulin resistance, hypertension, 
dyslipidemia, and impaired glucose regulation. 
With the worldwide obesity epidemic, the pre-
valence of  the metabolic syndrome is steadily 
increasing [15], currently present in 25% of  
middle-aged Finns and 80% of  patients with 
type 2 diabetes [16].  
Notably, a Scandinavian study suggests that pa-
tients with type 1 diabetes have a higher energy 
intake of  fat than age-matched subjects without 
diabetes [17], which may promote obesity in 
these subjects. One would therefore expect that 
in line with the worldwide obesity epidemic also 
patients with type 1 diabetes will become more 
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obese and encounter problems with reduced in-
sulin sensitivity and metabolic abnormalities re-
lated to insulin resistance. In patients with type 
1 diabetes, insulin resistance has been implicated 
in the pathogenesis of  both micro- and macro-
vascular complications [18,19], and the other 
components of  the metabolic syndrome also 
act as risk factors for diabetic complications. No 
studies exist, however, on the presence and the 
consequence of  such a cluster of  risk factors, 
the metabolic syndrome, in patients with type 
1 diabetes.  
Type 1 diabetes – epidemiology and 
pathogenesis
Type 1 diabetes is an autoimmune disease that 
results from an interaction between genetic and 
environmental factors. The disease is characteri-
zed by loss of  function of  the β-cells of  the pan-
creatic islets of  Langerhans and leads to absolu-
te insulin deficiency. The discovery of  insulin in 
1921 by Paulescu, and soon thereafter, the first 
successful administration of  exogenous insulin 
to humans by Banting and Best revolutionized 
the treatment of  diabetes. The incidence of  type 
1 diabetes varies in children from 0.1 in Vene-
zuela to 64 per 100,000 person-years in Finland, 
the country with the highest incidence rate in 
the world [2,20]. The pathophysiology of  type 
1 diabetes is still not fully understood, but the 
disease clusters in families. Recent Finnish data 
show a 43% probandwise concordance of  type 
1 diabetes in monozygotic twins [21], and the 
cumulative incidence of  type 1 diabetes is 7% by 
the age of  20 if  one of  the parents has diabetes, 
and even higher if  the father has diabetes [22]. 
Of  the genes identified, the human leukocyte 
antigen (HLA) class II genes are associated with 
the highest risk of  type 1 diabetes, confering 
about 50% of  the genetic susceptibility [23]. 
The HLA region is a complex entity, but the 
haplotypes DRB1*0401/2/4/5-DQB1*0302 
and DRB1*03-DQA1*05-DQB1*02 are asso-
ciated with the highest risk of  type 1 diabetes, 
whereas DRB1*15-DQA1*0102-DQB1*0602 
is the most common among the haplotypes that 
protect from diabetes [24]. A genetic suscepti-
bility by itself  is, however, not enough, requi-
ring also extrinsic factors that alter the immune 
system to trigger and sustain the development 
of  the disease. Potential factors include viral in-
fections and early exposure to cow’s milk pro-
teins [25], as well as birth by Cesarean section, 
high birth weight, and greater maternal age [26]. 
Activation of  the immune system by trigge-
ring factors leads to an inflammatory response, 
β-cell autoimmunity/insulitis, characterized by 
the appearance of  auto-antibodies [27], gradual 
loss of  β-cells, and eventually clinical disease. 
The incidence of  type 1 diabetes is rapidly in-
creasing worldwide, and there is a trend towards 
decreasing age at presentation [28]. In Finland, 
the incidence rate has doubled between 1980 
and 2005, and a steeper increase has been ob-
served since the late 1990s [2]. At the same time, 
protective HLA genotypes have become more 
frequent among patients with type 1 diabetes, 
suggesting that environmental pressure has be-
come more important and that penetrance of  
the disease is observed despite lower genetic 
risk [29]. Different theories have been pro-
posed for the increase in the incidence of  type 
1 diabetes. One theory is the accelerator hypothesis, 
which proposes that the tempo of  the β-cell 
loss is accelerating in modern society due to an 
increase in body weight, leading to a younger 
onset and thereby a higher incidence of  type 1 
diabetes [30].  In line with this, a Swedish study 
showed that the total incidence of  type 1 diabe-
tes has not increased, but the onset of  diabetes 
has in fact shifted towards an earlier age [28]. 
The increase in incidence of  type 1 diabetes 
seems to correlate with the observed increase 
in body weight in Finnish adolescents [3], but 
recent data from Finland suggest that there is 
in fact a true increase in the incidence, as the 
incidence of  type 1 diabetes is also increasing 
among 15 to 39-year-olds [31]. Another theory, 
the hygiene hypothesis, suggests that the increase 
in incidence is explained by improved hygiene, 
which has led to a decrease in infections during 
childhood [32]. This theory is supported by the 
incidence of  type 1 diabetes being lower in areas 
with higher population density and household 
crowding [33], and the incidence also correlates 
with the gross national product [34]. In addi-
tion, although the high-risk HLA genotypes are 
equally common among people on both sides 
of  the Finnish-Russian border, the incidence 
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of  type 1 diabetes is 6-fold higher in Finland, 
where the socioeconomic circumstances are 
better [35].
Type 2 diabetes – epidemiology and 
pathogenesis
Type 2 diabetes is characterized by insulin re-
sistance in target tissues and defects in insulin 
secretion in pancreatic β-cells, both of  which 
result from an interaction between genetic and 
environmental factors. The prevalence of  type 
2 diabetes varies between different populations, 
being approximately 5 to 10% in European 
populations, 15 to 20% in Hispanic Americans, 
and above 50% in Pima Indians [36]. The in-
cidence of  type 2 diabetes is increasing world-
wide, and in the United States, for instance, the 
incidence has increased from 267 in 1970 to 445 
per 100,000 person-years in 1994 in males [37]. 
In Finland, the register of  the Social Insurance 
Institution showed that 42,000 adults were using 
antidiabetic medication in 1970, while the num-
ber had increased to 135,000 in 2002 [38]. Type 
2 diabetes is usually diagnosed in adulthood, but 
today the incidence is increasing also in adoles-
cents [31]. Type 2 diabetes clusters in families, 
and in population-based studies the proband-
wise concordance in monozygotic twins is 34 
to 50% [39,40]. The risk of  type 2 diabetes in 
offspring of  a parent with type 2 diabetes is 16 
to 35%, and even higher if  both parents have 
diabetes [10,41]. Type 2 diabetes has a slow on-
set and can go undiagnosed for many years. The 
metabolic disturbances in the patients range 
from mild to severe, and therefore, common-
ly implemented treatments vary from dietary 
modifications and changes in lifestyle combined 
with oral hypoglycemic agents to insulin [42,43]. 
Type 2 diabetes often coincides with obesity 
and the metabolic syndrome, both of  which are 
also risk factors for type 2 diabetes, alongside 
lower levels of  physical activity [44,45]. Of  the 
measurements of  obesity, waist circumference 
seems to be the best predictor of  type 2 diabe-
tes, followed by the waist-to-hip ratio and the 
body mass index [46].
Decreased insulin action in the target tissues, in-
cluding muscle, liver, and adipose tissue, is a cen-
tral feature of  type 2 diabetes and is observed 
already years before disease onset. Defective in-
sulin secretion also plays an important role and 
is thought to be the factor driving disease onset 
[47,48]. Insulin resistance results from a com-
bination of  genetic and environmental factors 
and is closely associated with obesity, age, high-
caloric diet, and lack of  exercise [48]. The devel-
opment of  β-cell dysfunction occurs early in the 
disease process [49] and is first characterized by 
a decreased first-phase insulin response to glu-
cose, which leads to postprandial hyperglycemia 
and reflective hyperinsulinemia. Although the 
pathogenesis is not yet entirely clear, glucose 
toxicity, lipotoxicity, and β-cell exhaustion are 
factors thought to play a role in the initiation 
of  β-cell dysfunction, and consequently, to lead 
to inadequate responsiveness of  the β-cells to 
glucose and even loss of  β-cell mass by apop-
tosis [48]. 
Impact of family history of type 1 and 
type 2 diabetes
Type 1 and type 2 diabetes aggregate in the 
same families, suggesting that these two entities 
could share a common background. Compared 
with the general population, patients with type 
1 diabetes have more type 2 diabetes in their 
families [9,50], and type 1 diabetes is more fre-
quent in families of  patients with type 2 diabetes 
[9,51]. Both parental type 1 and type 2 diabetes 
increase the risk of  type 1 diabetes in siblings of  
probands with type 1 diabetes [52].  In line with 
this, the accelerator hypothesis suggests that type 1 
and type 2 diabetes in fact represent a disease 
continuum where the rate of  β-cell loss in addi-
tion to different genetic susceptibility determine 
the disease presentation [30].  
In patients with type 2 diabetes, a family his-
tory of  type 1 diabetes, compared with a family 
history of  type 2 diabetes, is associated with a 
higher prevalence of  high-risk HLA genotypes 
and a lower body mass index [53]. In patients 
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with type 1 diabetes, first-degree relatives show 
clustering of  other autoimmune disorders, the 
most common being autoimmune thyroid dis-
ease [54]. The effect of  maternal and paternal 
type 1 diabetes might differ since an excess pa-
ternal transmission of  type 1 diabetes has been 
observed [22,51].
Nondiabetic first-degree relatives of  patients 
with type 2 diabetes are insulin resistant and 
have an impaired insulin secretion [11], espe-
cially if  microalbuminuria is present [55]. In ad-
dition, compared with subjects without a family 
history of  diabetes, they show components of  
the metabolic syndrome [12], vascular dysfunc-
tion [56], and chronic low-grade inflammation 
[57]; all important in the pathogenesis of  the 
metabolic syndrome, type 2 diabetes, and com-
plications of  diabetes. Evidence suggests that 
the effect of  a maternal and a paternal history 
of  type 2 diabetes may differ. First, an excess 
maternal transmission of  type 2 diabetes has 
been reported in many studies [58,59], and sec-
ond, the metabolic consequences observed in 
offspring of  parents with type 2 diabetes seem 
to vary according to whether it is the father or 
the mother who has type 2 diabetes [60,61]. 
Data on the consequences of  a family history of  
type 2 diabetes on offspring with type 1 diabetes 
are scarce. Some support for an effect of  type 
2 diabetes is provided by the Diabetes Control 
and Complications Trial (DCCT), where im-
provement in glycemic control in the intensive 
treatment arm led to an increase in weight gain 
and triglyceride concentrations, particularly in 
those with a positive family history of  type 2 
diabetes [62].
Other forms of diabetes
In addition to type 1 and type 2 diabetes, other 
forms of  diabetes exist. Latent autoimmune 
diabetes in adults (LADA) resembles both type 
1 and type 2 diabetes and shares genetic fea-
tures with both [63]. Whether classification of  
LADA as a distinct entity has any clinical value 
has been questioned [64],  although some au-
thors strongly argue for the categorization of  
subtypes of  diabetes [65]. 
Idiopathic type 1 diabetes, also called type 1B 
diabetes, is a strongly inherited form of  diabe-
tes predominantly observed in subjects of  Asian 
or African origin. It does not involve autoim-
munity, and the need for insulin therapy varies 
between episodes. Maturity onset diabetes of  
the young (MODY) results from monogenetic 
defects in β-cell function, has an early age at on-
set, and is inherited in an autosomal dominant 
pattern. Other monogenetic forms of  diabetes 
include mutations in mitochondrial DNA caus-
ing deafness and diabetes. Also diseases of  the 
pancreas, for instance pancreatitis or pancreas 
cancer, can cause diabetes by destruction of  
pancreatic tissue. Moreover, some drugs, such 
as glucocorticoids, can influence glucose me-
tabolism, impairing insulin action in target tis-
sues [66]. 
Diabetic complications
Diabetes can result in chronic diabetic vascu-
lar complications in both patients with type 1 
and type 2 diabetes. Complications related to 
other forms of  diabetes will not be covered in 
this thesis. The vascular complications can be 
divided into microvascular and macrovascular 
complications. Microvascular complications af-
fect the small vessels of  the body, especially in 
the kidneys (nephropathy), retina of  the eyes 
(retinopathy), and the nerves (neuropathy). 
Macrovascular complications affect the large 
vessels, for instance the coronary, cerebral, and 
peripheral arteries. The diabetic complications 
are strongly associated with the excess mortal-
ity observed in patients with diabetes [67], and 
also result in a great burden on the health care 
system [4], and most importantly, a reduction 
in patient’s health-related quality of  life [68,69]. 
The following sections include a review of  dia-
betic complications, with the main focus on 
nephropathy and macrovascular disease in pa-
tients with type 1 diabetes.
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Nephropathy
Characterization of diabetic nephropathy and 
renal function
The first clinical sign of  diabetic nephropathy 
is an increased urinary albumin excretion rate 
in the range of  ≥20<200 μg/min, or ≥30<300 
mg/24-hours, called microalbuminuria [70]. Be-
low this range, the albumin excretion rate is clas-
sified as normal, and if  ≥200 μg/min or ≥300 
mg/24-hours, considered as macroalbuminuria 
or overt diabetic nephropathy.
 
Renal function can be directly measured as the 
plasma clearance of  inulin or exogenous mark-
ers, such as 51Cr-EDTA. This is, however, com-
plex and expensive, and thus, not feasible in rou-
tine clinical practice, estimates have therefore 
been developed for the assessment of  glomeru-
lar filtration rate. The most widely used method 
is the Cockcroft-Gault formula for estimated 
creatinine clearance [71], adjusted for body 
surface area. The more recent Modification of  
Diet in Renal Disease formula was developed 
to estimate creatinine clearance in patients with 
chronic renal disease [72]. Of  these two, the 
Cockcroft-Gault formula is more accurate in 
the normal and upper-normal range of  glom-
erular filtration [73], while the Modification of  
Diet in Renal Disease formula seems to be more 
accurate in patients with chronic renal disease. 
Both are estimates of  creatinine clearance and 
not specifically glomerular filtration. Creatinine 
clearance generally overestimates the glomeru-
lar filtration because of  the tubular secretion of  
creatinine. Serum cystatin C has therefore been 
suggested as a new tool to measure renal func-
tion, and it seems to be superior to the crea-
tinine-based formulas in detecting a decline in 
renal function [74]. Renal function is classified 
based on glomerular filtration rate into normal 
≥90, mild decrease in renal function 60 to 89, 
moderate decrease in renal function 30 to 59, 
severe decrease in renal function 15 to 29, and 
renal failure <15 ml/min/1.73 m2 [75]. 
Epidemiology
Diabetic nephropathy is characterized by el-
evated blood pressure, proteinuria, and often 
a relentless decline in renal function, and its 
presence is associated with a high cardiovascu-
lar morbidity and early mortality [5]. Diabetic 
nephropathy is the most common cause of  re-
nal replacement therapy in the Western world 
[76]. One-third of  patients with type 1 diabetes 
will develop diabetic nephropathy [7,77], and in 
a recent Finnish study, after 30 years of  diabe-
tes, 8% had developed end-stage renal disease. 
Notably, in this study, the prognosis of  patients 
with diabetic nephropathy had improved during 
the past four decades, and children diagnosed 
with type 1 diabetes before the age of  five had 
the most favorable prognosis [78]. It is evident 
that not only the incidence of  end-stage renal 
disease, but also the overall incidence of  diabet-
ic nephropathy has decreased in patients whose 
diagnosis of  type 1 diabetes has occurred more 
recently [79,80], due to improved treatment and 
earlier detection of  nephropathy. 
Pathogenesis
Diabetic nephropathy is characterized by glom-
erulosclerosis of  the kidney, which leads to leak-
age of  proteins into the urine and a reduction in 
the glomerular filtration rate. Early in the dis-
ease process, glomerular hyperfiltration occurs 
due to increased capillary pressure in the glom-
eruli, but further morphologic changes contrib-
ute to decreased glomerular filtration [81]. Such 
changes include mesangial expansion, increased 
permeability of  the glomerular endothelial cells, 
thickening and decreased negative charge of  the 
basement membrane, and hypertrophy, detach-
ment, and apoptosis of  the podocytes [82].
For the development of  diabetic nephropathy, 
the diabetic milieu is a prerequisite, but how the 
hyperglycemia induces damage to the vascula-
ture is not fully understood. Oxidative stress 
has been proposed as the unifying factor be-
hind the following four main molecular mecha-
nisms through which hyperglycemia is thought 
to cause vascular damage [83]: 1) Activation of  
the polyol pathway, which is a relatively inactive 
pathway at normal glucose concentrations, leads 
to conversion of  glucose to sorbitol by aldose re-
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ductase, which again leads to reduced NADPH 
and glutathione availability, contributing to in-
tracellular oxidative stress. 2) The irreversible 
nonenzymatic reaction of  reducing sugars and 
proteins leads to formation of  advanced glyca-
tion end-products, which can alter the function 
of  the proteins, cause generalized cellular dys-
function, and bind to specific receptors, gener-
ating reactive oxygen species. 3) Hyperglycemia 
also increases protein kinase C activity, leading 
to activation of  growth factors and decreased 
endothelial nitric oxide synthase activation. 4) 
Increased activity of  the hexosamine pathway 
due to hyperglycemia causes, for example, in-
creased gene expression of  growth factors, such 
as transforming growth factor β-1.
Oxidative stress is thought to result in endothe-
lial dysfunction, which precedes albuminuria in 
patients with type 1 diabetes [84], and accord-
ingly, glomerular endothelial dysfunction as well 
as insulin resistance have been suggested to 
initiate the cascade that leads to diabetic neph-
ropathy [85,86].
The increased intraglomerular pressure caused 
by the constriction of  efferent glomerular ar-
terioles is thought to result from an activation 
of  the renin-angiotensin system. This system 
is a major player in blood pressure control and 
fluid homeostasis. Renin converts angiotensino-
gen to angiotensin I, which is further converted 
to angiotensin II by angiotensin-converting en-
zyme. Angiotensin II is thought to be the key 
promoter of  vascular damage through its ac-
tions via angiotensin type 1 receptor. How and 
why the renin-angiotensin system is activated 
are unknown, but hyperglycemia per se seems to 
increase renin activity [87], and the renin-angio-
tensin system is also activated by inflammatory 
cytokine interleukin-6 [88]. Specific inhibitors 
of  the renin-angiotensin system are effective in 
the treatment of  diabetic nephropathy [89]. 
Other factors involved in the pathogenesis 
of  diabetic nephropathy include activation of  
growth factors, such as transforming growth 
factor β-1, connective tissue growth factor, 
growth hormone, insulin-like growth factor-1, 
and vascular endothelial growth factor. These 
factors contribute to the formation of  fibrotic 
changes in the mesangium and the interstitium, 
glomerular hypertrophy, and dysfunction of  
glomerular endothelial cells [85]. Activation of  
inflammatory cytokines, such as interleukin-1, 
interleukin-6, and tumor necrosis factor α, is 
also involved in the pathogenesis of  diabetic 
nephropathy [90].
Risk factors
Microalbuminuria. Microalbuminuria can be 
viewed as both a marker and a risk factor for 
diabetic nephropathy. Screening for microalbu-
minuria identifies patients with incipient diabetic 
nephropathy and is an effective tool for detect-
ing risk of  overt disease [91], although some pa-
tients with normal albumin excretion rate also 
show diabetic renal lesions [92]. Normal albu-
min excretion is associated with a 17% cumula-
tive incidence of  microalbuminuria over 5 to 10 
years in patients who have had type 1 diabetes 
for at least 7 years. Early studies suggested an 
80% risk of  progression from microalbuminuria 
to macroalbuminuria [93-95], while more recent 
data indicate that the risk is approximately 30% 
over 5 to 10 years [96,97], while in those with 
diabetes duration of  less than 15 years the risk 
seems to be higher, around 45% [98]. Regres-
sion of  the albumin excretion rate also occurs. 
Regression from macroalbuminuria to microal-
buminuria, or from macroalbuminuria to a nor-
mal albumin excretion rate, is observed in 20 to 
30% of  patients during follow-up [96,97], and 
some studies even indicate a greater regression 
rate [99]. It is noteworthy that microalbuminu-
ria in type 2 diabetes is also associated with sim-
ilar progression rates to macroalbuminuria as in 
type 1 diabetes [97], but the structural changes 
in the kidneys vary considerably, and only 30% 
of  patients with type 2 diabetes and microal-
buminuria present with typical diabetic glom-
erulopathy [82,97]. The strongest risk factors 
for onset or progression of  microalbuminuria 
include an increase in albumin excretion within 
the normal range and poor glycemic control 
along with disease duration [100]. 
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Genetic predisposition. Strong evidence sug-
gests that diabetic nephropathy results from an 
interaction between susceptibility genes and the 
diabetic milieu [101]. The incidence peak occurs 
15 to 20 years after onset of  diabetes, and there-
after the risk declines [7,102], indicating that 
not all patients with type 1 diabetes will develop 
nephropathy. Diabetic nephropathy clusters in 
families of  patients with type 1 [8,101,103] and 
type 2 diabetes [104-106], and in specific ethnic 
groups [107-109]. In patients with type 1 diabe-
tes, Seaquist et al. showed that 83% of  siblings 
of  probands with diabetic nephropathy had dia-
betic nephropathy, whereas the prevalence was 
only 17% in siblings of  probands without dia-
betic nephropathy [8]. 
Studies on familial factors in diabetic nephropa-
thy in type 1 diabetes are summarized in Table 
1. A family history of  hypertension has been 
associated with diabetic nephropathy in many 
studies [110-119], suggesting that a genetic 
predisposition to hypertension is linked to an 
increased risk of  diabetic nephropathy. Not all 
studies, however, support this finding [120-124]. 
Since patients with type 1 diabetes and diabetic 
nephropathy have a several-fold increased risk 
of  cardiovascular disease, genetic factors that 
contribute to an increased risk of  cardiovas-
cular disease could theoretically also explain 
some of  the risk of  diabetic nephropathy. A pa-
rental history of  cardiovascular morbidity and 
mortality has accordingly been associated with 
Table 1. Parental factors associated with diabetic nephropathy in type 1 diabetes
n Mean age HT DM2 DM1 CVD Mort IR
Viberti 1987 110 34 27 + –
Krolewski 1988 119 89 30 +
Jensen 1990 120 98 28 – –
Walker 1990 132 40 31 +/–
Nørgaard 1991 127 112 30 – – –
Barzilay 1992 112 162 29 +
Earle 1992 125 122 42 + +
Molitch 1993 121 715 27 –
Yip 1993 129 18 42 +/– +
Freire 1994 113 42 13 +
DeCosmo 1997 114 62 35 + – + +/– +
Erbey 1998 128 658 33 +
Fagerudd 1998 115 146 37 + + –
Roglic 1998 116 3,250 33 + +
Rudberg 1998 117 300 20 + – – +/–
Fagerudd 1999 118 137 42 + + – +
Lindsay 1999 126 236 42 +
Verhage 1999 123 57 32 – – – – –
Campos-Pastor 2000 119 312 32 +
Tarnow 2000 122 326 41 – – +/– +
Fagerudd 2003 131 82 38 –
Hadjadj 2004 130 275 41 +/– +/– +
Harjutsalo 2004 124 1,153 - – +
Hadjadj 2007 134 160 42 – + +/–
Monti 2007  322 4,389 34 + –
HT =hypertension, DM2 = type 2 diabetes, DM1 = type 1 diabetes, CVD = cardiovascular disease, Mort =  early overall mortality 
or mortality from cardiovascular disease, IR = insulin resistance, DN = diabetic nephropathy
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a higher prevalence of  diabetic nephropathy 
[114,118,122,125,126], and also an increase in 
cardiovascular disease among patients with dia-
betic nephropathy [125]. However, many stud-
ies show contradictory results [115,123,127]. 
In addition, family history of  insulin resistance 
and type 2 diabetes has been associated with 
diabetic nephropathy in some but not all studies 
[114-118,120,122-124,127-131]. Many of  these 
studies on familial risk factors have been small 
and have had insufficient power to evaluate 
the effect of  maternal and paternal risk factors 
separately. Furthermore, whether a clustering 
of  risk factors in parents increases the risk for 
diabetic nephropathy in offspring with type 1 
diabetes is unclear.
Several candidate gene studies have been per-
formed in the search for susceptibility genes 
for diabetic nephropathy. These studies have, 
however, often been carried out in a relatively 
small number of  patients, and have generated 
many positive associations that other studies 
have been unable to replicate. Interesting genes 
recognized by this approach include the angio-
tensin-converting enzyme insertion/deletion 
polymorphism that was associated with diabetic 
nephropathy in a large meta-analysis [133], and 
this association was later confirmed in a Eu-
ropean study of  patients with type 1 diabetes 
[134]. Another potential susceptibility gene, the 
UNC13B, was recently identified, and also rep-
licated in an independent population. This gene 
is upregulated by hyperglycemia and mediates 
apoptosis in glomerular cells [135]. A genome-
wide linkage analysis of  Finnish patients with 
type 1 diabetes suggested that there is a locus 
for diabetic nephropathy on chromosome 3q 
[136]. Further fine-mapping and analysis of  
this region yielded a significant association with 
a novel endothelium enhancer, and this find-
ing was replicated in several populations [137]. 
Genome-wide association studies enable the 
search for genes involved in pathways not yet 
recognized in the pathogenesis of  the specific 
disease. Such work is ongoing in several labo-
ratories, and recently, two novel candidate loci 
were identified by this approach, including loci 
near the FRMD3 and CARS genes [138].
Glycemic control. Glycosylated hemoglobin A1c 
(HbA1c) is the most widely used measure of  
glycemic control, reflecting the lifespan of  he-
moglobin, and thus, the glucose exposure over 
the past 2 to 3 months [139]. The beneficial ef-
fect of  improved glycemic control for diabetic 
nephropathy was shown in early intervention 
studies, such as the Kroc Collaborative Study, 
the Steno Study, the Oslo Study, and the Stock-
holm Diabetes Intervention Study [140-143]. 
These studies had a rather low number of  pa-
tients followed over a relatively short time, and 
therefore, the final evidence was not provided 
until results from the large DCCT were pub-
lished [144]. The DCCT randomized patients 
with type 1 diabetes, short duration of  diabetes, 
and no signs of  microvascular complications 
into intensive and conventional insulin therapy. 
During 6.5 years of  follow-up, intensive treat-
ment resulted in significantly improved glycemic 
control compared with conventional treatment 
(mean HbA1c 7% vs. 9%). Intensive compared 
with conventional insulin therapy resulted in a 
39% reduction in the incidence of  microalbu-
minuria and a 54% reduction in the incidence 
of  overt diabetic nephropathy [144]. Eight years 
after the closure of  the DCCT, the glycemic 
control between the two groups of  insulin ther-
apy were similar (HbA1c  8%), but the beneficial 
effect of  intensive therapy on the development 
of  diabetic nephropathy was sustained, with a 
59% reduction in the incidence of  microalbu-
minuria and 84% reduction in the incidence of  
overt nephropathy [145]. These results suggest 
that lifetime exposure of  hyperglycemia and gly-
cemic memory is important in the pathogenesis 
of  diabetic nephropathy. The beneficial effect 
of  good glycemic control is further highlighted 
by the reassuring findings of  persistent normo-
glycemia 10 years after simultaneous renal and 
pancreas transplantation, which resulted in re-
versal of  diabetic renal lesions in a small group 
of  eight patients [146]. Although this approach 
is not feasible in larger patient cohorts, it high-
lights the importance of  good glycemic control 
even at this late stage of  renal disease.
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Hypertension. Type 1 diabetes is associated with 
hypertension, also in patients without renal in-
volvement, compared with subjects without 
diabetes [147]. In patients with type 1 diabe-
tes, diabetic nephropathy is clearly associated 
with hypertension. Hypertension both parallels 
[148,149] and precedes [150,151] the worsening 
of  renal disease. Accordingly, aggressive treat-
ment of  hypertension improves the prognosis 
of  patients with diabetic nephropathy [152,153], 
especially with the use of  angiotensin-convert-
ing enzyme inhibitors and angiotensin receptor 
blockers with beneficial effects beyond blood 
pressure-lowering effects [154,155]. For diag-
nosis of  hypertension, most studies have used 
office blood pressure measurements, which do 
not reflect the daily variation in blood pressure 
levels. Accordingly, 24-hour ambulatory blood 
pressure measurements are more sensitive in 
identification of  patients at risk. Patients with 
diabetic nephropathy show an absence of  the 
normal dip in nocturnal blood pressure, which 
may reflect dysfunction of  the autonomic ner-
vous system [156].
Dyslipidemia. Dyslipidemia in patients with 
type 1 diabetes is associated with poor glycemic 
control, hypertension, and obesity [157], and 
parallels the worsening of  renal disease [157-
159]. Lipid abnormalities have even been sug-
gested to be more closely linked to microvas-
cular than macrovascular complications in type 
1 diabetes [160]. Patients with type 1 diabetes 
have elevated high-density lipoprotein (HDL)-
cholesterol [161] due to the stimulating effect 
of  insulin on lipoprotein lipase activity [162]. 
Low HDL-cholesterol and elevated triglycer-
ides, both components of  the metabolic syn-
drome, are associated with abdominal obesity in 
patients with type 1 diabetes [163]. Few studies 
have addressed the role of  lipids in the progres-
sion of  renal disease. Mulec et al. showed total 
cholesterol, triglycerides, and apolipoprotein B 
to be risk factors for progression of  renal dis-
ease in a small study [164], while regarding the 
development of  renal failure, no effect was ob-
served for triglycerides and total cholesterol in 
a larger study [150]. Data from our own group 
suggest that different lipid abnormalities are 
involved at different stages of  progression. 
Low-density lipoprotein (LDL)-cholesterol was 
associated with progression to microalbuminu-
ria, while triglycerides predicted progression to 
macroalbuminuria [165]. 
Obesity. Obesity has been pointed out as one 
of  the risk factors for the development of  end-
stage renal disease in the general population 
[166]. Interestingly, in patients with type 1 dia-
betes, abdominal obesity has also been linked to 
the risk of  diabetic nephropathy. Waist-to-hip 
ratio was one of  the factors predicting develop-
ment of  microalbuminuria in a 7-year follow-
up in the EURODIAB Prospective Complica-
tions Study [167], and a 10-cm greater waist 
circumference at the DCCT closeout was as-
sociated with a 1.34-fold increased risk of  mi-
croalbuminuria over 6 years of  follow-up [168]. 
In addition to the potential role of  obesity in 
the development of  microalbuminuria, body 
weight has been implicated in the development 
of  macroalbuminuria [169]. Interestingly, com-
pared with subcutaneous fat, intra-abdominal 
fat, which is related to atherogenic dyslipidemia 
in patients with type 1 diabetes [170], seems to 
be more strongly related to albuminuria [171].
Insulin resistance. Insulin resistance is observed 
in patients with type 1 diabetes of  varying dura-
tion and is associated with poor glycemic con-
trol and increased body weight [172,173]. The 
insulin resistance in type 1 diabetes is reflected 
in peripheral tissues as well as in increased he-
patic glucose production [174]. Using the eug-
lycemic hyperinsulinemic clamp technique, the 
golden standard for the measurement of  insulin 
sensitivity [175], patients with microalbuminuria 
have been shown to be insulin resistant [176], 
and insulin resistance to precede the develop-
ment of  microalbuminuria [177]. Another study 
found no association between insulin sensitivity 
and albumin excretion rate [178]. This measure-
ment is, however, complex, time-consuming, 
and invasive, and therefore, a surrogate estimate 
of  the glucose disposal rate has been developed 
[179]. Using this surrogate estimation, insulin 
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resistance has been shown to predict overt dia-
betic nephropathy in a large cohort [18]. The in-
sulin dose adjusted for body weight can also be 
used as a surrogate marker of  insulin sensitivity 
in subjects on insulin therapy [180]. The insu-
lin dose correlates negatively with the estimated 
glucose disposal rate (r = -0.48) [179], but insu-
lin dose does not seem to be a good predictor 
of  progression of  renal disease [167,169,177]. 
Interestingly, pharmacological treatment of  in-
sulin resistance with thiazolidinediones seems 
to have beneficial effects beyond glycemic con-
trol and reduces microvascular complications, 
at least in patients with type 2 diabetes [181]. 
Taken together, these data favor the view that 
insulin resistance not only parallels but also pre-
cedes the development of  diabetic nephropathy 
in patients with type 1 diabetes.
Other factors. Many other factors have also been 
shown to increase the risk of  diabetic nephrop-
athy. Male gender seems to be associated with 
increased risk [7], along with smoking [182] 
and advanced glycation, expressed as limited 
joint mobility [183] and plantar fascia thickness 
[184]. Diabetic nephropathy is further associat-
ed with chronic low-grade inflammation [185]. 
The predictive risk associated with markers of  
inflammation is, however, less clear [186,187], 
although markers of  inflammation are strongly 
related to endothelial dysfunction [188], which 
is a risk factor for diabetic nephropathy and de-
cline in renal function [84,186,187].
Retinopathy
Diabetic retinopathy is the leading cause of  
blindness in the Western world. With effective 
screening and treatment, an estimated 90% of  
visual loss can be prevented [189]. The severity 
of  diabetic retinopathy is classified based on the 
Early Treatment Diabetic Retinopathy Study 
severity scale into different stages of  nonpro-
liferative and proliferative retinopathy. Nonpro-
liferative retinopathy is observed in almost all, 
whereas the sight-threatening proliferative retin-
opathy is seen in 15 to 50%, of  patients with 
type 1 diabetes after 15 to 20 years of  diabetes 
[190,191]. Early changes in the retina include 
microaneurysms, intraretinal hemorrhage, and 
cotton wool spots, whereas proliferative retin-
opathy is characterized by ischemia-induced 
neovascularization of  the retina. These new 
vessels tend to bleed, thereby causing vitreous 
hemorrhage. Neovascularization can also occur 
elsewhere, for example in the trabecular mesh-
work, resulting in neovascular glaucoma [192]. 
Diabetic macular edema leads to thickening of  
the retina in the macular region, causing major 
threat to vision. Macular edema is observed in 
10 to 15% of  patients with type 1 diabetes after 
15 years of  diabetes [191].
Diabetic retinopathy, especially proliferative 
retinopathy, clusters in families [193,194], indi-
cating a genetic predisposition. Diabetic retin-
opathy often coincides with other diabetic com-
plications, particularly diabetic nephropathy. 
The severity of  diabetic retinopathy is associ-
ated with the severity of  glomerular morpho-
logic changes [195] and also with the severity of  
clinical nephropathy [194]. The DCCT showed 
a beneficial effect of  intensive treatment of  
hyperglycemia on the development of  diabetic 
retinopathy [144], and the effect sustained even 
after the intensive therapy ended, although the 
glycemic control worsened [196]. In addition to 
the classic risk factors for retinopathy, duration 
of  diabetes and poor glycemic control, factors 
related to insulin resistance have been shown to 
increase the risk of  retinopathy [197]. Screening 
for diabetic retinopathy by regular fundus pho-
tography or ophthalmoscopy plays a key role 
in the identification of  patients at risk. Good 
glycemic control is essential for the treatment 
of  diabetic retinopathy, as is the treatment of  
hypertension and dyslipidemia. Retinal laser 
photocoagulation is needed in cases with severe 
proliferative retinopathy and macular edema to 
improve the visual prognosis of  patients [192]. 
Neuropathy
Diabetic neuropathy is the most common cause 
of  neuropathies worldwide, and sensorimotor 
polyneuropathy starting from the most distal 
end of  the feet and extending proximally with 
time is the most predominant form of  diabetic 
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neuropathy. The longest nerve fibers are first af-
fected, through both degeneration of  axons and 
demyelination [198]. Symptoms include numb-
ness, burning sensation, stabbing pain, loss of  
thermal sensation, loss of  vibratory sensation, 
and loss of  proprioception, and can result in 
painless trauma, for example chronic foot ulcers 
and Charcot arthropathy. Poor glycemic control 
and duration of  diabetes are risk factors for dia-
betic neuropathy. Hyperglycemia is thought to 
damage the nerves at least via advanced glycated 
end-products [199]. No effective cure exists for 
this irreversible complication of  diabetes, and 
therefore, primary prevention through good 
glycemic control [144] is the most important 
goal. Regular clinical foot examination and pa-
tient education are necessity in the secondary 
prevention of  chronic foot ulcers. 
 
Autonomic neuropathy is observed in approxi-
mately 20% of  asymptomatic patients with dia-
betes. Dysfunction of  the autonomic nervous 
system can be life-threatening, especially when 
the cardiac autonomic nervous system is affect-
ed. Autonomic neuropathy is associated with si-
lent myocardial ischemia and increased mortal-
ity. Findings of  autonomic neuropathy include 
resting tachycardia, exercise intolerance, pos-
tural hypotension, gastroparesis, atonic bladder, 
and impotence [200]. 
 
Another less common form of  diabetic neu-
ropathy is focal and multifocal neuropathy, 
which mainly affects older patients with type 2 
diabetes. This form of  neuropathy has a rapid 
onset and spontaneous recovery, and the patho-
genesis includes both inflammation and nerve 
ischemia. Around 20% of  patients with concur-
rent diabetes and neuropathy present with other 
neuropathies than diabetic neuropathies, the 
most common being chronic inflammatory de-
myelinating neuropathy and pressure palsy, such 
as carpal tunnel syndrome [198]. 
Macrovascular complications
Epidemiology
Macrovascular disease in type 1 diabetes has 
been investigated to a far lesser extent than 
microvascular complications, although type 
1 diabetes is associated with a significant and 
high risk of  cardiovascular disease [201,202], 
especially in patients with diabetic nephropathy 
[5,201,203,204]. Limited data on cerebrovascu-
lar disease and peripheral vascular disease ex-
ist in patients with type 1 diabetes, and in many 
cases the results are pooled to a common cardio-
vascular end-point. Thus, the following section 
reviews the literature on macrovascular disease, 
with the main focus on coronary heart disease, 
and presents data on other macrovascular com-
plications when available and appropriate. 
Cardiovascular disease is observed in 25% of  
middle-aged patients with type 1 diabetes [205], 
and early studies suggest that compared with 
subjects without diabetes, mortality from car-
diovascular disease is 2 to 7 times higher in pa-
tients with type 1 diabetes [67,203]. In patients 
with type 1 diabetes without diabetic neph-
ropathy, the risk of  cardiovascular mortality is 
4 times higher than in the general population, 
and the presence of  diabetic nephropathy adds 
to the risk 9 to 10 times, compared with the ab-
sence of  diabetic nephropathy [5,206]. Recent 
data show in patients with type 1 diabetes 9 
and 42 times higher standardized mortality ra-
tios from ischemic heart disease in males and 
females aged under 40 years, respectively, and 4 
and 7 times higher mortality in those above 40 
years [202]. 
Although the incidence of  diabetic nephropa-
thy is decreasing, the incidence of  cardiovas-
cular disease shows no trend towards decline 
[207]. The cardiovascular disease observed in 
patients with type 1 diabetes shows some dis-
parities compared with that observed in the 
general population. The protective effect of  
female gender is not observed in type 1 diabe-
tes, consequently leading to higher standard-
ized incidence and mortality rates in females 
[202,208,209]. In addition, asymptomatic myo-
cardial ischemia is a common finding in patients 
with type 1 diabetes [210], especially in patients 
with diabetic nephropathy [211]. Furthermore, 
with the same symptoms, patients with type 1 
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diabetes have a more severe coronary artery dis-
ease [212] and the atherosclerosis occurs earlier 
and is more diffuse [213]. 
Pathogenesis
Cardiovascular disease results from atheroscle-
rosis, which is characterized by accumulation of  
lipids and fibrous elements in the walls of  the 
large arteries. Hyperglycemia activates differ-
ent molecular pathways that lead to intracellular 
oxidative stress, as discussed earlier regarding 
diabetic nephropathy [83]. The formation of  
reactive oxygen species, in addition to hyperten-
sion and altered lipoproteins, then leads to en-
dothelial dysfunction, which again results in va-
soconstriction, as well as pro-inflammatory and 
pro-thrombotic changes, contributing to plaque 
development. Endothelial dysfunction activates 
adhesion molecules and chemotactic factors, 
leading to adhesion and penetration of  mono-
cytes into the arterial media, where they differ-
entiate into macrophages. Lipids then accumu-
late intracellularly and cause lesions called fatty 
streaks. Smooth muscle cells migrate from the 
media to the intima of  the vascular wall, where 
they proliferate in response to growth factors 
to form the fibrous cap of  the atherosclerotic 
plaque. A large lipid core and thin fibrous cap 
predispose to plaque rupture, while the pres-
ence of  a thick fibrous cap marks a more stable 
plaque. Myocardial infarctions and other acute 
clinical events are usually caused by plaque rup-
ture and thrombosis. [214]
Risk factors
Microalbuminuria. As mentioned earlier, dia-
betic nephropathy is by far the strongest risk 
factor for cardiovascular disease in patients with 
type 1 diabetes. Importantly, even a slightly in-
creased albumin excretion rate, both in the nor-
mal range [215] and in the range of  microalbu-
minuria [216], predicts atherosclerotic vascular 
disease. Microalbuminuria is also a potent risk 
factor for cardiovascular disease in the general 
population and in patients with type 2 diabetes 
[217], and thought to reflect a more generalized 
vascular damage, and not only an increased risk 
for diabetic nephropathy [85,218].
Genetic predisposition. A family history of  car-
diovascular disease has been associated with 
cardiovascular disease in patients with diabetic 
nephropathy [125]. In addition, a family his-
tory of  type 2 diabetes has been associated with 
coronary heart disease [128], and in another 
study both a family history of  type 2 diabetes 
and hypertension were associated with an inter-
mediate marker of  atherosclerosis, the carotid 
intima-media thickness [219].
Glycemic control. The role of  glycemic control in 
cardiovascular disease has only recently started 
to unravel. Weak associations between glycemic 
control and coronary heart disease have been 
observed in some [220] but not all earlier studies 
[19,208]. The DCCT originally showed a 41% 
risk reduction in cardiovascular disease by inten-
sive treatment of  diabetes. This risk reduction 
was, however, not statistically significant in the 
young patients with few cardiovascular events 
[144]. Six years after the DCCT closeout, the in-
tensive treatment received during the DCCT, de-
creased the progression of  carotid intima-media 
thickness [221]. Twelve years after the DCCT 
closeout, the effect of  intensive treatment was 
preserved, resulting in a 42% lower risk of  any 
cardiovascular events, an observation that was 
significant also after adjustment for albuminu-
ria [222]. Similarly, coronary artery calcification 
was measured with computed tomography eight 
years after the end of  DCCT, and patients with 
prior intensive treatment had less atherosclero-
sis mainly due to reduced HbA1c levels during 
the DCCT [223]. Suboptimal glycemic control 
was also a strong risk factor for progression of  
coronary artery calcification in a smaller study 
[224]. Recent data from the DCCT show poor 
glycemic control to be a risk factor for the de-
velopment of  hypertension, which again is a risk 
factor for cardiovascular disease [225]. Further 
evidence for the role of  poor glycemic control 
in type 1 diabetes comes from a meta-analysis 
showing that improvement of  glycemic control 
results in a 62% lower risk of  macrovascular 
events [226]. Also recent prospective studies 
demonstrate a beneficial effect of  good glyce-
mic control on cardiovascular morbidity and 
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mortality in type 1 diabetes [209,227,228]. 
Hypertension. Hypertension has been dem-
onstrated in many studies to increase the risk 
of  cardiovascular morbidity and mortality in 
patients with type 1 diabetes [19,204,229,230]. 
Some studies have not been able to show an ef-
fect of  hypertension independently of  diabetic 
nephropathy [208], while in other studies the 
risk associated with hypertension has been re-
stricted to females [216].
Dyslipidemia. Cardiovascular disease in type 1 
diabetes is associated with higher triglycerides 
and lower HDL-cholesterol [205], as well as 
with changes in the composition of  the lipo-
proteins [231]. In prospective studies, elevated 
total cholesterol [229] and low HDL-cholesterol 
[19,208,230] have been shown to predict cardio-
vascular disease. High triglycerides seem to in-
crease the risk of  cardiovascular disease primar-
ily in females [216].
Obesity. A measure of  abdominal obesity, the 
waist-to-hip ratio, has been associated with in-
creased risk of  cardiovascular disease in both 
males and females with type 1 diabetes [208,216]. 
Body mass index, a general measure of  obesity, 
has been associated with the progression of  
coronary artery calcification [232].
Insulin resistance. Early studies reported that 
insulin resistance is associated with atheroscle-
rosis [233], and also with the progression of  
atherosclerotic disease in follow-ups of  7 years 
[234] and 18 years of  the same cohort of  pa-
tients with type 1 diabetes [235]. In addition, 
independent relationships between an estimate 
of  insulin resistance and both cardiovascular 
events [19] and coronary artery calcification 
have been observed [236].
Other factors. Cardiac autonomic neuropathy is 
a strong risk factor for cardiovascular morbid-
ity [200,216], and reduced heart rate variability, 
a measure of  autonomic dysfunction, has been 
associated with coronary artery calcification 
in patients with type 1 diabetes [237]. Chronic 
low-grade inflammation and endothelial dys-
function also increase the risk of  cardiovascular 
morbidity and mortality [187,230,238]. In addi-
tion, smoking increases the risk of  both periph-




Risk factors associated with cardiovascular 
disease, including impaired glucose regulation, 
central obesity, dyslipidemia, and hypertension, 
tend to cluster in the same individuals. Reaven 
called this syndrome the Syndrome X, a cluster 
of  insulin resistance with dyslipidemia and hy-
pertension [239]. Kaplan added abdominal obe-
sity to the syndrome, and named it the Deadly 
Quartet [240]. Thereafter, the syndrome has 
also been called the insulin resistance syndrome 
[241], but today this syndrome is known world-
wide as the metabolic syndrome. 
Already in the 18th century, Morgagni described 
the coexistence of  visceral fat accumulation 
with metabolic abnormalities and cardiovascu-
lar disease [242]. This matter was reawakened 
in 1923, when Kylin presented his hyperten-
sion-hyperglycemia-hyperuricemia syndrome 
[243]. It was not, however, until 1998 that the 
first definition of  the metabolic syndrome was 
introduced by the World Health Organization 
(MSWHO) [244], and the definition was further 
modified in 1999 with lower cut-off  values for 
blood pressure [245].  Several sets of  definitions 
with different main emphases have since been 
introduced by different organizations (Table 2). 
Both MSWHO and the definition provided by the 
European Group for the study of  Insulin Re-
sistance (MSEGIR) [246] highlight the importance 
of  impaired glucose regulation. The definitions 
by the National Cholesterol and Education 
Program Adult Treatment Panel III (MSNCEP) 
[247] and the American Heart Association and 
the National Heart, Lung, and Blood Institute 
(MSAHA/NHLBI) [248] give all the components 
equal importance and define the disturbance in 
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glucose regulation by impaired fasting glucose. 
The definition by the International Diabetes 
Federation (MSIDF) [249] considers abdominal 
obesity as the central feature and also provides 
ethnicity-specific cut-off  values for waist cir-
cumference. Irrespective of  which definition is 
used, the main components of  the syndrome 
remain the same. Notably, the MSWHO is the 
only one to include microalbuminuria, which 
is a strong predictor of  cardiovascular dis-
ease [217]. The earlier definitions, MSWHO and 
MSEGIR, included insulin resistance as a specific 
component [245,246], however, the exact mea-
surement of  insulin sensitivity is difficult, and 
later definitions have therefore instead includ-
ed fasting plasma glucose as a measure of  im-
paired glucose regulation. Of  note is that none 
of  the definitions for the metabolic syndrome 
has taken into consideration patients with type 
1 diabetes. 
Epidemiology
With the worldwide increase in obesity, the 
metabolic syndrome has become a frequently 
observed condition, and the many definitions 
provided have enabled assessment of  the prev-
alence of  the metabolic syndrome in different 
populations. In Finland, the metabolic syn-
drome is observed in 39% and 22% of  middle-
aged males and females, respectively, according 
to a modified MSWHO definition [250], and the 
prevalence of  the metabolic syndrome increas-
es with age [16]. In young Finnish adults, the 
prevalence is 13% , 14%, and 10% according 
to MSNCEP, MSIDF, and MSEGIR, respectively, and 
a 7-fold increase in the metabolic syndrome in 
24-year-olds from 1986 to 2001 has emerged, 
driven mainly by an increase in obesity and dys-
lipidemia [15]. An increase in the metabolic syn-
drome has also been observed in middle-aged 
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WHO = World Health Organization, EGIR = European Group for the study of  Insulin Resistance, NCEP = National Cholesterol 
Education Program Adult Treatment Panel III, IDF = International Diabetes Federation, AHA/NHLBI = American Heart 
Association/National Heart, Lung, and Blood Institute, IGT = impaired glucose tolerance, BMI = body mass index, WHR = waist-to-
hip ratio, M = males, F = females, UAER = urinary albumin excretion rate. 
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[251]. According to the MSNCEP definition, the 
prevalence in adult males worldwide ranges 
from 10% in France and India, to 15 to 20% in 
Australia, Ireland, and Italy, and further to 25% 
in Turkey. In females, the prevalence is less than 
10% in France, 20% in Australia, Ireland, and 
Oman, and 40% in Iran and Turkey [252]. In 
the United States, the overall prevalence is 22%, 
exceeding 40% in those aged over 60 years. 
The metabolic syndrome is also more common 
among Mexican Americans and African Ameri-
can females [253]. A considerable overlap exists 
between the different definitions, as MSWHO and 
MSNCEP identify with 86% accuracy the same in-
dividuals [254].  
Cardiovascular disease and the metabolic syn-
drome
In a recent meta-analysis, the metabolic syn-
drome was shown to increase the risk of  cardio-
vascular morbidity and mortality 1.5- and 1.7-
fold, respectively [255], and this increased risk 
is observed in both the general population and 
patients with type 2 diabetes [16,256-258]. The 
metabolic syndrome is consequently a frequent 
finding in patients with cardiovascular disease, 
being observed in 40 to 50% of  patients with 
manifest disease [259,260]. The metabolic syn-
drome increases the progression of  carotid ath-
erosclerosis [261] and worsens the prognosis of  
patients with cardiovascular disease [259,260]. 
The MSNCEP compared with the MSIDF, is a bet-
ter predictor of  future outcome of  patients with 
established vascular disease [259,260]. 
 
Diabetes and the metabolic syndrome 
The metabolic syndrome increases with more 
pronounced disturbances in glucose regulation, 
being 12% in subjects with normal glucose tol-
erance, 53% in subjects with either impaired 
fasting glucose or impaired glucose tolerance, 
75% in subjects with impaired glucose toler-
ance, and 87% in subjects with type 2 diabetes 
[16,250]. The metabolic syndrome is thought to 
be a pre-diabetic state, associated with a 3-fold 
risk of  developing type 2 diabetes [44,262,263]. 
Type 2 diabetes is also associated with a worse 
prognosis after a cardiovascular event [264,265]. 
The role of  the metabolic syndrome in patients 
with type 1 diabetes is unknown. 
Renal disease and the metabolic syndrome 
More recently, attention has been drawn to the 
association of  the metabolic syndrome with 
chronic renal disease. In subjects without diabe-
tes, the metabolic syndrome has been associated 
with the presence [266] as well as the develop-
ment of  chronic renal disease [14]. In patients 
with type 2 diabetes, the metabolic syndrome is 
associated with a 4-fold risk ratio for microal-
buminuria, an association mainly driven by hy-
pertension [267]. A metabolic profile related to 
insulin resistance has also been associated with 
a reduction in renal function in patients with 
type 2 diabetes [268]. The association of  the 
metabolic syndrome with renal disease is un-
surprising given the strong association between 
cardiovascular and renal disease. Moreover, in-
sulin resistance, dyslipidemia, and hypertension 
are all risk factors for renal disease and also co-
occur with renal disease.
Other conditions and the metabolic syndrome
The metabolic syndrome is also associated with 
many other conditions. A reciprocal association 
exists between psychological distress and the 
metabolic syndrome. During a 7-year follow-
up of  middle-aged women, depression, tension, 
and anger increased the risk of  the metabolic 
syndrome, which in turn increased the risk of  
developing anxiety [269]. Chronic schizophre-
nia is associated with a considerable increase in 
the prevalence of  the metabolic syndrome, driv-
en by adverse metabolic effects of  antipsychotic 
medication, along with such life style factors as 
smoking, lack of  exercise, and poor diet [270]. 
Polycystic ovary syndrome is considered to be 
an insulin resistant state, and the metabolic syn-
drome has accordingly been associated with this 
condition [271]. In addition, sleep apnea is asso-
ciated with an increased prevalence of  the meta-
bolic syndrome, and the association is thought 
to be mediated via fragmentation of  sleep and 
hypoxia, and to result in metabolic disorders via 
oxidative stress, inflammation, and activation of  
the sympathetic nervous system [272]. Further-
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more, the metabolic syndrome is a risk factor for 
prostate cancer, especially in obese individuals 
[273], and also increases the risk of  other forms 
of  cancer, for example colon cancer [274]. The 
metabolic syndrome is also more common in 
subjects who smoke and are less physically ac-
tive, observed especially in those who belong to 
lower social classes [275].
Pathogenesis
Insulin resistance has been proposed as the un-
derlying factor behind the clustering of  the met-
abolic abnormalities observed in the metabolic 
syndrome [239]. Figure 1 depicts the pathophys-
iology of  the metabolic syndrome and insulin 
resistance [252]. An overabundance of  free fatty 
acids, as a result of  increased lipolysis in adipose 
tissue, especially in visceral deposits, plays a ma-
jor role in the development of  insulin resistance 
[276]. Free fatty acids reduce insulin-mediated 
glucose uptake in muscles and increase glucose 
production in the liver by impaired insulin ac-
tion and enhanced gluconeogenesis. In the liver, 
free fatty acids also increase secretion of  triglyc-
eride-rich very low-density lipoproteins, leading 
to decreased HDL-cholesterol and increased 
density of  LDL-cholesterol. 
Lipoprotein lipase plays a central role in the me-
tabolism of  triglyceride-rich particles and low 
activity of  lipoprotein lipase leads to elevated 
triglycerides and low HDL-cholesterol. Lipo-
protein lipase activity is insulin-dependent, and 
is thus low in insulin resistance and also in in-
sulin deficiency [162]. Furthermore, increased 
circulating glucose and also free fatty acids to 
some extent lead to increased insulin secretion 
of  pancreatic β-cells, resulting in hyperinsuline-
mia. Hyperinsulinemia further causes sodium 
reabsorption in the kidneys and increased cen-
tral nervous system activity, contributing to hy-
pertension [252]. 
In obesity, the adipose tissue is characterized by 
enlarged adipocytes and increased macrophage 
infiltration. The enlarged adipocytes produce 
increased amounts of  proinflammatory cytok-
ines, such as interleukin-6, which together with 
the macrophage-produced tumor necrosis fac-
Figure 1. Pathogenesis of the metabolic syndrome and insulin resistance. Reprinted from The Lancet 365, Eckel 
RH, Grundy SM, and Zimmet PZ, The metabolic syndrome, pages 1415-1428, Copyright © 2005, with permission 
from Elsevier.
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tor α, are involved in impaired insulin signal-
ing. Adipocytes also produce adipokines, such 
as leptin and the anti-inflammatory adiponec-
tin [277]. The increased secretion of  cytokines 
combined with decreased adiponectin secretion 
lead to increased free fatty acid release. They 
also contribute to insulin resistance in muscles 
and liver and have direct harmful effects on the 
vasculature, eventually leading to atherosclero-
sis [278]. Adipocytes also secrete angiotensino-
gen, thereby contributing to hypertension via 
activation of  the renin-angiotensin system. In 
addition, plasminogen activator inhibitor-1 pro-
duction by adipose tissue is increased in obesity, 
contributing to a prothrombotic state [277].
In addition, neuroendocrine dysregulation of  
the hypothalamic-pituitary-adrenal axis may be 
involved in the metabolic syndrome. In males, 
low testosterone levels lead to muscular insu-
lin resistance and in combination with elevated 
cortisol to fat accumulation in visceral deposits. 
In females, high levels of  adrenal androgens via 
activation of  the hypothalamic-pituitary-adrenal 
axis lead to insulin resistance.[279] 
Components of the metabolic syndrome
Insulin resistance
Insulin resistance is defined as a reduced bio-
logical effect for a given insulin concentration 
[180]. There are several ways to measure insulin 
resistance. The euglycemic clamp technique is 
the golden standard [175], although time-con-
suming and thus used only in studies with small 
numbers of  patients. In subjects without ex-
ogenous insulin therapy, an alternative method 
for measuring insulin resistance is the minimal 
model, which assesses the profiles of  insulin 
and glucose during an intravenous glucose tol-
erance test. While these two methods assess the 
stimulated insulin resistance, the homeostasis 
assessment model estimates basal insulin resis-
tance. The homeostasis assessment model is a 
mathematical model based on fasting plasma 
glucose and insulin concentrations, and can 
thus be performed in large study populations. 
A more simplistic approach, although not as ac-
curate, is to measure fasting insulin [180].  Insu-
lin resistance as an independent cardiovascular 
risk factor is somewhat contradictory. Not all 
studies have been able to demonstrate a positive 
association, but a meta-analysis showed hyper-
insulinemia to be a risk factor for cardiovascu-
lar disease [280]. Insulin resistance is, however, 
strongly associated with both the individual 
components of  the metabolic syndrome, such 
as triglycerides, low HDL-cholesterol, hyper-
tension, obesity, and albuminuria [281], and the 
cluster of  these components [282,283]. Insulin 
resistance adds to the value of  MSNCEP in the 
prediction of  cardiovascular events, even after 
adjustment for traditional risk factors and type 
2 diabetes [284]. Insulin resistance also predicts 
the development of  type 2 diabetes indepen-
dent of  obesity [285].
Abdominal obesity
Insulin resistance is characteristic of  obesity, 
although lean people can also be insulin resis-
tant [286]. Obesity is associated with all of  the 
components of  the metabolic syndrome [287]. 
Visceral fat, in contrast to subcutaneous fat, is 
especially harmful, and measured by the waist-
to-hip ratio, visceral fat is independently associ-
ated with an increased cardiovascular risk, after 
adjustment for body mass index and other car-
diovascular risk factors [288]. Detection of  vis-
ceral fat by magnetic resonance imaging shows 
waist circumference to be superior to waist-
to-hip ratio and body mass index in detecting 
visceral fat [289,290]. Visceral fat is thought to 
have adverse metabolic effects due to higher 
turnover rate and flux of  free fatty acids to the 
liver [252]. 
Dyslipidemia
In line with the proposed pathophysiology be-
hind the metabolic syndrome, high levels of  
triglycerides and low levels of  HDL-cholester-
ol are associated with insulin resistance [239]. 
Especially the combination of  these two lipid 
abnormalities is associated with a number of  
other metabolic disturbances as well, while low 
HDL-cholesterol without elevated triglycerides 
is not associated with insulin resistance or ab-
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dominal obesity [291]. In addition, insulin resis-
tance seems to precede the development of  dys-
lipidemia [292]. Small dense LDL-cholesterol is 
frequently observed in patients with the meta-
bolic syndrome, but is often not an independent 
risk factor for cardiovascular disease [293]. 
Hypertension
The association between hypertension and insu-
lin resistance is weaker than for the other com-
ponents, although abundant data favor the view 
that hypertension is a true component of  the 
metabolic syndrome. Lean hypertensive patients 
are insulin resistant [294], and in subjects with 
normal glucose regulation, fasting insulin, an in-
dicator of  insulin resistance, is associated with 
hypertension [295]. In addition, fasting insulin 
also predicts the development of  hypertension 
[292]. Furthermore, subjects with normal blood 
pressure, but with a family history of  hyperten-
sion, are more insulin resistant and have higher 
triglycerides and lower HDL-cholesterol than 
subjects without this family history [296,297]. 
Hypertensive subjects also have elevated trig-
lycerides and lower HDL-cholesterol [298], and 
the cluster of  atherogenic lipid abnormalities 
might even precede the development of  hyper-
tension [299]. Hypertensive patients with the 
metabolic syndrome also have higher urinary 
albumin excretion, despite similar blood pres-
sure values, than those without the metabolic 
syndrome [300]. In patients with hypertension, 
the metabolic syndrome is associated with a 
43% increased risk of  cardiovascular events, 
after adjustment for traditional risk factors and 
diabetes [301]. 
Albuminuria
The MSWHO is the only definition to include 
microalbuminuria in the metabolic syndrome 
[245]. Albuminuria is associated with insulin re-
sistance in patients with hypertension, and the 
presence of  diabetes is associated with a further 
reduction in insulin sensitivity [302,303].  Sub-
jects with a cluster of  type 2 diabetes, hyperten-
sion, and microalbuminuria have a dyslipidemia 
typical of  the metabolic syndrome [303]. Al-
buminuria is also associated with an increased 
waist-to-hip ratio in healthy subjects receiving 
no medication [304].
Other metabolic abnormalities
The metabolic syndrome is also closely associ-
ated with metabolic abnormalities other than 
those included in the definitions of  the syn-
drome. The metabolic syndrome is associated 
with elevated uric acid [305], as well as with 
decreased levels of  adipokines and increased 
levels of  inflammatory cytokines, and the pro-
thrombotic plasminogen activator inhibitor-1 
[306]. Nonalcoholic fatty liver is closely associ-
ated with the components of  the metabolic syn-
drome [307]. Of  the markers of  inflammation, 
C-reactive protein is established as a cardiovas-
cular risk factor. Elevated C-reactive protein is 
associated with obesity [308], the development 
of  hypertension [309], and an increased risk of  
the metabolic syndrome [308]. The combina-
tion of  C-reactive protein and the metabolic 
syndrome adds to the risk of  developing car-
diovascular disease beyond the risk associated 
to the metabolic syndrome alone. This suggests 
that C-reactive protein could work as an addi-
tional component of  the metabolic syndrome 
[310]. Moreover, a low birth weight combined 
with a catch-up in body weight is associated 
with the occurrence of  the metabolic syndrome 
later in life [311]. This could indicate that fetal 
and childhood growth plays a role in the devel-
opment of   metabolic disturbances leading to 
the metabolic syndrome, cardiovascular disease, 
and diabetes, a theory initiated by Barker [312].  
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The aims of  this study were as follows:
 
To investigate the association between parental history of  hypertension, cardiovascular I 
disease, and diabetes, and diabetic nephropathy in offspring, in a large cohort of  patients 
with type 1 diabetes, and to assess whether clustering of  such traits in families increases 
the likelihood of  diabetic nephropathy. Another aim was to investigate whether parents of  
patients with diabetic nephropathy have an increased total or cardiovascular mortality.
To evaluate the effect of  parental history of  type 2 diabetes on offspring with type 1 diabetes, II 
with regard to their metabolic profile and the presence of  the metabolic syndrome and 
diabetic late complications. 
To assess the prevalence of  the metabolic syndrome in Finnish patients with type 1 diabetes III 
and to evaluate whether it is associated with diabetic nephropathy or poor glycemic control.
To assess the predictive value of  different definitions of  the metabolic syndrome for IV 
cardiovascular events, cardiovascular and diabetes-related mortality, and progression of  
diabetic nephropathy in patients with type 1 diabetes. 
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Figure 2. Map of Finland with each dot indicating the 
home address of one FinnDiane Study subject. The 
distribution is similar to the distribution of people in 
Finland in general, with most people living in the sout-
hern parts of the country.
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The FinnDiane Study – general aspects
All patients are part of  the nationwide FinnDi-
ane Study that was launched on November 21, 
1997, at the Helsinki University Central Hos-
pital, Department of  Medicine, Division of  
Nephrology. The aims of  the study are to col-
lect a large cohort of  adult patients with type 
1 diabetes (25%) from all over Finland, and to 
find genetic, clinical, and environmental risk 
factors for micro- and macrovascular compli-
cations in type 1 diabetes. The study includes 
77 centers participating in the collection of  pa-
tients, including all 5 University Hospitals, all 16 
Central Hospitals, 26 regional hospitals, and 30 
primary health care centers (see Appendix). The 
local ethics committees have approved the study 
protocol, and the study has been carried out in 
accordance with the Declaration of  Helsinki 
[313]. Written informed consent was obtained 
from each patient.
The FinnDiane Study consists of  three phases 
that being conducted in parallel. Phase I includes 
a visit to collect baseline data of  patients with 
type 1 diabetes. Phase I is ongoing, and by No-
vember 2008, a total of  4,805 patients with type 
1 diabetes had participated, that is approximate-
ly 12% of  all 40,000 patients with type 1 dia-
betes in Finland. The patients are from all over 
Finland, as shown in Figure 2.    
 
In phase II of  the FinnDiane Study, parents and 
siblings of  the patients with type 1 diabetes 
are investigated. By November 2008, a total of  
1,652 parents and 799 siblings had participated. 
Two different approaches are used. The primary 
approach includes a visit to one of  the study 
centers and collection of  clinical and labora-
tory data (n = 965). The secondary approach 
includes mailing out a questionnaire and test 
tubes for blood samples that are then drawn at 
the participant’s local laboratory and sent to the 
FinnDiane Study by mail (n = 1,450). Finally, in 
some cases, house calls have been made to col-
lect both clinical and laboratory data (n = 36).
Phase III of  the FinnDiane Study consists of  
collection of  follow-up data of  the patients with 
type 1 diabetes who have participated in phase 
I of  the study. Phase III was initiated in 2004, 
is still ongoing, and the goal is to re-study all 
patients who participated in phase I. By Novem-
ber 2008, altogether 1,268 patients had been 
re-studied. Alternative approaches to collect 
follow-up data include visiting hospital archives 
to review the medical files of  patients or order-
ing specific medical files (n = 3,108). 








Males (%) 59 48 <0.001
Age (years) 42.1 ± 9.4 40.6 ± 11.6 0.002
Age at diabetes onset (years) 11.6 ± 7.1 13.6 ± 8.3 <0.001
Duration of  diabetes (years) 30.4 ± 8.0 27.0 ± 9.6 <0.001
Body mass index (kg/m2) 25.2 ± 3.9 25.1 ± 3.3 0.594
Waist circumference (cm) 89 ± 12 85 ± 11 <0.001
Total cholesterol (mmol/l) 5.46 ± 1.11 4.94 ± 0.87 <0.001
LDL-cholesterol (mmol/l) 3.44 ± 0.94 3.01 ± 0.81 <0.001
HDL-cholesterol (mmol/l) 1.26 ± 0.39 1.45 ± 0.47 <0.001
Triglycerides (mmol/l) 1.41 (1.02-2.03) 0.93 (0.70-1.26) <0.001
Lipid-lowering medication (%) 23 9.0 <0.001
Treatment with acetylsalicylic acid (%) 32 9.5 <0.001
HbA1c (%) 8.9 ± 1.5 8.3 ± 1.3 <0.001
eGDR (mg/kg/min) 4.0 (3.1-5.0) 6.4 (4.6-8.5) <0.001
Insulin dose (IU/kg) 0.67 (0.54-0.80) 0.66 (0.54-0.80) 0.780
eGFR (ml/min/1.73m2) 60 ± 35 101 ± 29 <0.001
UAER (mg/24h) 499 (171-1274) 11 (6-29) <0.001
Systolic blood pressure (mmHg) 147 ± 21 133 ± 16 <0.001
Diastolic blood pressure (mmHg) 84 ± 11 79 ± 9 <0.001
Antihypertensive medication (%) 95 34 <0.001
ACE-inhibitors/AT2-blockers (%) 57/9.6 24/3.9 <0.001
Coronary heart disease (%) 15 4.1 <0.001
Myocardial infarction (%) 8.6 1.9 <0.001
Stroke (%) 7.2 1.1 <0.001
Amputations (%) 11 1.1 <0.001
Smoking (%) 25 22 0.144
Age of  mothers (years) 66.6 ± 10.0 64.6 ± 11.6 <0.001
Age of  fathers (years) 66.0 ± 8.7 64.2 ± 10.4 0.005
Age at death of  mothers (years) 69.3 ± 13.7 69.4 ± 12.9 0.958
Age at death of  fathers (years) 63.8 ± 13.2 64.1 ± 13.7 0.753
Data are means ± standard deviations, medians (interquartile ranges), or percentages. eGDR = estimated glucose disposal rate, eGFR 
= estimated glomerular filtration rate, UAER = urinary albumin excretion rate.
For patients who have died, death certificates 
are ordered to retrieve information on time and 
cause of  death (see more detailed information 
in the Methods section). 
All clinical data, laboratory data, genetic data, 
and data from questionnaires are entered into 
the web browser-based platform BC/GENE 
version 3.0 (Biocomputing Platforms Ltd., Es-
poo, Finland). When the different studies were 
performed, the complete data set available from 
the database at the time of  each study was used, 
and the selection criteria for each study are pro-
vided below.
Study I
The design for Study I is cross-sectional. By 
May 2005, the study included 2,355 patients 
with type 1 diabetes for whom the diabetic renal 
status was classifiable and information on either 
parent was available. Of  the patients, 51% were 
male, mean age was 41.1 ± 10.9 years (mean ± 
standard deviation), and duration of  diabetes 
was 28.2 ± 9.2 years. Information was available 
for 2,353 mothers and 2,323 fathers, a total of  
4,676 parents. More detailed clinical character-
istics of  the patients, grouped by the presence 
or absence of  diabetic nephropathy, are shown 
in Table 3.
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Type 1 diabetes and complete data on the 
metabolic syndrome, renal status, and 
parental medical history 
n = 3,271




Unknown type of 
parental diabetes
n = 145




No parental history of type 
2 diabetes
n = 2,417
Positive parental history of type 2 
diabetes
n = 620
Negative parental history of type 2 
diabetes, matched for age and gender
n = 1,240
Random selection
Figure 3. Selection of patients for Study II. 
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Study II
The design for Study II is cross-sectional. The 
study includes 1,860 patients with type 1 dia-
betes. The selection of  patients for the study 
is shown in Figure 3. In March 2006, complete 
information on the metabolic syndrome, renal 
status, and parental medical history was avail-
able for 3,037 patients. A clear age difference 
was present between patients with a positive pa-
rental history of  type 2 diabetes, compared with 
those with a negative parental history (43.9 ± 
10.2 vs. 36.0 ± 11.5 years, P<0.001), and there-
fore of  the 2,417 patients with a negative paren-
tal history of  type 2 diabetes, a total of  1,240 
age-matched patients were randomly selected as 
controls. The matching for age was first done by 
dividing those with a positive parental history 
of  type 2 diabetes into octiles regarding age. 
Those with a negative parental history of  dia-
betes were then ordered by a random number 
from zero to one. Thereafter the controls were 
chosen, within the same age-limits, in numerical 
order in 1:2 ratio from each age group. More 
detailed clinical characteristics of  the patients, 
grouped by their family history of  type 2 diabe-
tes, are shown in Table 8 (Section 6).





Males (%) 50 52 0.448
Age (years) 38.7 ± 11.6 36.2 ± 11.5 <0.001
Age at diabetes onset (years) 14.5 ± 8.2 15.7 ± 8.7 0.001
Duration of  diabetes (years) 24.1 ± 11.1 20.5 ± 11.8 <0.001
Body mass index (kg/m2) 26.6 ± 4.0 24.0 ± 2.7 <0.001
Waist-to-hip ratio (cm) 0.90 ± 0.09 0.85 ± 0.08 <0.001
Total cholesterol (mmol/l) 5.21 ± 1.01 4.82 ± 0.87 <0.001
LDL-cholesterol (mmol/l) 3.34 ± 0.90 2.93 ± 0.81 <0.001
HDL-cholesterol (mmol/l) 1.10 ± 0.30 1.43 ± 0.35 <0.001
Triglycerides (mmol/l) 1.53 ( 1.03-2.11) 0.92 (0.74-1.18) <0.001
Lipid-lowering medication (%) 16 6.1 <0.001
Treatment with acetylsalicylic acid (%) 17 7.2 <0.001
HbA1c (%) 8.8 ± 1.6 8.3 ± 1.4 <0.001
eGDR (mg/kg/min) 4.5 (3.2-6.1) 7.2 (4.9-8.8) <0.001
Insulin dose (IU/kg) 0.71 (0.58-0.87) 0.67 (0.55-0.82) <0.001
Creatinine (µmol/l) 92 (79-117) 84 (76-95) <0.001
eGFR (ml/min/1.73m2) 89 (65-105) 94 (79-108) <0.001
Systolic blood pressure (mmHg) 140 ± 19 130 ± 18 <0.001
Diastolic blood pressure (mmHg) 83 ± 10 78 ± 10 <0.001
Antihypertensive medication (%) 61 30 <0.001
ACE-inhibitors/AT2-blockers (%) 39/7.1 21/3.3 <0.001
Coronary heart disease (%) 8.7 3.4 <0.001
Myocardial infarction (%) 5.1 1.5 <0.001
Stroke (%) 3.1 1.5 0.009
Diabetic nephropathy (%) 37 14 <0.001
Retinal laser treatment (%) 53 26 <0.001
Smoking (%) 26 22 0.037
Data are means ± standard deviations, medians (interquartile ranges), or percentages. eGDR = estimated glucose disposal rate, eGFR 
= estimated glomerular filtration rate.
Study III
The design for Study III is cross-sectional. The 
study includes 2,415 patients with type 1 diabe-
tes for whom complete lipid profiles and clini-
cal data on the components of  the metabolic 
syndrome were available by April 2004. Of  the 
patients, 51% were male, mean age was 37.1 ± 
11.6 years, and duration of  diabetes was 21.9 ± 
11.7 years. More detailed clinical characteristics 
of  the patients, grouped by the presence or ab-
sence of  the metabolic syndrome, are shown in 
Table 4.
Study IV
Study IV is a prospective study. The study in-
cludes 3,783 patients with type 1 diabetes in 
whom, at baseline, complete data on lipid pro-
files and clinical data on all of  the components 
of  the metabolic syndrome were available by 
March 2008. Of  the patients, 52% were male, 
mean age was 37.5 ± 11.8 years, and duration 
of  diabetes was 22.7 ± 12.2 years. More detailed 
clinical characteristics of  the patients, grouped 
by the presence or absence of  the metabolic 
syndrome, are shown in Table 5.































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































33Studies III and IV32 4 SUBJECTS AND STUDY DESIGNS
35The FinnDiane Study protocol34 5 METHODS
5 METHODS
The FinnDiane Study protocol
At the study centers, all adult patients with type 
1 diabetes were asked to participate, and the re-
sponse rate was 78% [314]. Data were collected 
during a regular visit to the patient’s attending 
physician, and included a thorough medical his-
tory, current medication of  the patients, and 
measurement of  weight, height, waist and hip 
circumferences, and blood pressure. In addi-
tion, blood samples were drawn, and a 24-hour 
urine collection performed. Patients answered a 
questionnaire about their medical history, his-
tory of  smoking, alcohol consumption, educa-
tion, employment, and medical history of  their 
siblings and parents. 
Definition of type 1 diabetes 
Type 1 diabetes was defined as onset of  diabetes 
before 35 years of  age and insulin treatment ini-
tiated within one year of  diagnosis of  diabetes. 
Anthropometric measurements
Weight was measured using a standardized scale 
and registered to the closest 0.1 kg. Height was 
registered to the closest 1 cm. Body mass in-
dex was calculated as weight divided by height 
squared (kg/m2). Waist circumference was mea-
sured midway between the lowest rib and the 
iliac crest, and hip circumferences at the wid-
est part of  the gluteal region. Waist-to-hip ratio 
was calculated as waist divided by hip circum-
ference. 
Assessment of blood pressure
Blood pressure was measured twice in the sit-
ting position after an initial 10-minutes rest, and 
the mean values for systolic and diastolic blood 
pressure were calculated. The blood pressure 
measurements were performed with a mercury 
sphygmomanometer, and Korotkoff  sounds I 
and V were registered as systolic and diastolic 
blood pressure, respectively. Due to regulations 
regarding the use of  mercury sphygmomanom-
eters in the health care service [315] (European 
Council Directive 93/42/EEC), automated 
standardized blood pressure devices have also 
been approved as an alternative method for mea-
surement of  blood pressure. Antihypertensive 
medication was defined as the current use of  
at least one antihypertensive drug, either angio-
tensin-converting enzyme inhibitor, angiotensin 
receptor antagonist, calcium channel blocker, 
β-blocker, diuretic, or other antihypertensive 
agents (mainly prazosin or moxonidine).
Definition of diabetic nephropathy and assess-
ment of renal function
Renal status was defined based on the urinary 
albumin excretion rate in at least two of  the 
three overnight or 24-hour urine collections. 
Normal urinary albumin excretion rate was de-
fined as urinary albumin <20 µg/min or <30 
mg/24h, microalbuminuria ≥20<200 µg/min or 
≥30<300 mg/24h, or macroalbuminuria ≥200 
µg/min or ≥300 mg/24h.  Patients on dialysis 
or with a renal transplant were classified to hav-
ing end-stage renal disease. In some patients, 
renal status could not be assessed due to recent 
onset of  diabetes, too few urine collections, or 
signs of  nondiabetic renal disease. These sub-
jects were excluded from Studies I and II, and 
from part of  the analyses in Studies II and IV. 
Diabetic nephropathy was defined as macroal-
buminuria or end-stage renal disease. In Study 
I, patients with a normal urinary albumin excre-
tion rate were required to have diabetes dura-
tion >15 years to ensure normal renal status. 
 
In Studies I and III, renal function was estimated 
by the Cockcroft-Gault formula for creatinine 
clearance, adjusted for body surface area [71]. 
An estimated glomerular filtration rate above 90 
ml/min/1.73m2 was considered normal, 60 to 
90 ml/min/1.73m2 was considered mild renal 
impairment, and below 60 ml/min/1.73m2 was 
considered moderate to severe renal impair-
ment, according to American National Kidney 
Estimated glucose disposal rate = 
24.4 - 12.97*WHR - 3.39*AHT - 
0.60*HbA1c
WHR stands for waist-to-hip ratio and 
AHT for antihypertensive treatment 
and/or blood pressure ≥140/90 mmHg 
(yes = 1, no = 0). 
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Foundation Kidney Disease Outcome Quality 
Initiative guidelines [75]. 
Definition of diabetic retinopathy
Retinal laser treatment was used as a marker of  
proliferative retinopathy. Signs of  any retinal 
changes due to diabetes were also registered, 
but were not used as a variable in this study. 
Definition of cardiovascular disease
Coronary heart disease was defined as diag-
nosed myocardial infarction, coronary revascu-
larization, or pharmacological treatment with 
long-acting nitroglycerin. A myocardial infarc-
tion was defined as a clinically verified event. 
Stroke was defined as cerebral infarction or in-
tracerebral hemorrhage. Cardiovascular events 
included diagnosed myocardial infarction, coro-
nary revascularization, or stroke. Amputations 
were defined as amputation of  any part of  the 
lower limbs. The cause for amputations was not 
registered. Treatment with lipid-lowering medi-
cation as well as with acetylsalicylic acid was also 
registered.
Definition of the metabolic syndrome
The metabolic syndrome was first introduced as 
a concept in type 1 diabetes in Study III and as-
sessed according to the MSNCEP definition [247]. 
In Study II, both MSNCEP and MSIDF [249] defi-
nitions were used, and in Study IV, the MSNCEP, 
MSIDF, and MSWHO [245] definitions were used 
for the diagnosis of  the metabolic syndrome 
(Table 2). All patients with type 1 diabetes were 
considered to fulfill the criteria for hyperglyce-
mia. A metabolic score (1-5) was also calculated 
based on the number of  criteria each patient 
fulfilled for the MSNCEP definition.
Assessment of glycemic control and insulin sen-
sitivity
Glycemic control was assessed based on one 
HbA1c measurement and classified as good 
(HbA1c <7.5%), intermediate (7.5-9.0%), or 
poor (>9.0%). As a measure of  insulin sensitiv-
ity, an equation for the estimated glucose dis-
posal rate was applied [179], modified for use of  
HbA1c instead of  HbA1. 
As another marker of  insulin sensitivity, the to-
tal daily insulin dose per body weight (IU/kg) 
was used.
Definition of smoking
Smoking was defined as current smoking of  at 
least one cigarette per day for at least one year.
Information on parents
Parental information was obtained from the 
patients with type 1 diabetes by a standardized 
questionnaire. Questions about mothers and 
fathers were asked separately, and included in-
formation on birth year, medical history of  dia-
betes, antihypertensive medication, myocardial 
infarction, and stroke. Parental cardiovascular 
disease was defined as a history of  myocardial 
infarction or stroke. If  the parent had diabetes, 
age at onset and mode of  treatment was regis-
tered (diet, oral hypoglycemic agents, or insulin), 
and based on this information the parental dia-
betes was classified as type 1 (age at onset <35 
years and insulin treatment), type 2 (age at onset 
>50 years, or if  age at onset was not registered, 
treatment with oral hypoglycemic agents or 
diet), or nonclassifiable (incomplete data on age 
at onset and/or treatment). If  the parent had 
died, the cause and time of  death was registered. 
Parental cardiovascular mortality was defined as 
death from myocardial infarction, heart failure, 
ruptured aortic aneurysm, or a cerebrovascular 
event. In Study II, of  the 620 patients with a 
parental history of  type 2 diabetes, 327 (53%) 
had an afflicted mother, 248 (40%) an afflicted 
father, and 45 (7%) had both parents afflicted. 
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Those with both parents with diabetes were ex-
cluded from the statistical subanalyses regarding 
maternal and paternal type 2 diabetes. 
Parental risk score 
In Study I, to assess the association of  different 
combinations of  a parental history of  hyperten-
sion, cardiovascular disease, and diabetes (type 
1 and type 2) with diabetic nephropathy in off-
spring, a parental risk score was used. Each par-
ent was given one point for each positive history 
of  hypertension, cardiovascular disease, and/or 
diabetes. If  the parent had no history of  these 
traits, the parental risk score was zero, and if  
the parent was positive for all three the score 
was three. The maximum parental score was 
thus six and the minimum zero. Combinations 
of  hypertension and cardiovascular disease or 
diabetes were also calculated, with a maximum 
possible score of  four. As expected, only a few 
patients had high scores and these scores were 
therefore pooled.
Validation of parental data
A total of  1,370 (29%) of  the 4,676 parents in 
Study I participated in the FinnDiane Study. 
They answered a standardized questionnaire 
regarding their medical history. In these cases, 
the information given by the patient with type 1 
diabetes could be directly validated. Data were 
validated for 625 fathers and 745 mothers of  
789 patients with type 1 diabetes. Mean time 
difference from when the data were given by the 
patient with type 1 diabetes to when the par-
ent personally attended the study was 3.1 ± 2.3 
(mean ± standard deviation) years for mothers 
and 2.9 ± 2.5 years for fathers. In some cases, 
the parents had been diagnosed with hyperten-
sion, cardiovascular disease, or diabetes during 
this period, and the data were corrected ac-
cordingly. The overall sensitivity of  the paren-
tal data was 83% and the specificity 98%. Re-
garding maternal/paternal data, the sensitivity 
for hypertension was 84/82%, myocardial in-
farction 75/91%, stroke 63/42%, and diabetes 
91/87%. 
Collection of follow-up data
Two different complementary approaches were 
used to collect follow-up data on the patients. 
First, the medical files were reviewed and any 
changes in renal status or occurrence of  cardio-
vascular events was verified. Second, patients 
were re-examined at their local medical center 
according to the same protocol as at the base-
line visit.
Cardiovascular events and progression of renal dis-
ease
Data collection on morbidity is ongoing, and 
in Study IV, data on cardiovascular events were 
available for 2,474 (65%), and on progression 
of  renal disease for 2,594 (69%) patients. Data 
were retrieved from follow-up visits, medical 
files, or death certificates. A new myocardial in-
farction was defined as a clinically verified event 
during follow-up (n = 161). Stroke was defined 
as cerebral infarction or intracerebral hemor-
rhage (n = 80). Cardiovascular events includ-
ed diagnosed myocardial infarction, coronary 
revascularization, or stroke (n = 263). Progres-
sion of  renal disease was defined as a change 
in category from normal urinary albumin excre-
tion to microalbuminuria (n = 118), from mi-
croalbuminuria to macroalbuminuria (n = 54), 
or from macroalbuminuria to end-stage renal 
disease (n = 130).
Mortality
On March 30, 2007, data on mortality were 
obtained from Statistics Finland, which main-
tains the national archive of  death certificates. 
Information was obtained on which patients 
had died, and for those who had died, copies 
of  the original death certificates were received. 
The death certificates included information on 
time of  death, cause of  death (immediate, con-
tributing, and underlying), where the patient 
died (home/hospital), type of  death (illness, 
accident, suicide, or unknown), a short report 
on the events prior to death, and whether the 
report was based on autopsy or clinical evalu-
ation. Of  the 3,783 patients in Study IV, 285 
(7.5%) had died. All death certificates were re-
evaluated to standardize the classification, and 
LDL-cholesterol =
 Total cholesterol – HDL-cholesterol – 
Triglycerides/2.2
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coded according to the immediate and underly-
ing causes of  death. The coding included eight 
different categories: 1) cardiovascular disease, 
2) cerebrovascular disease, 3) cancer, 4) infec-
tions, 5) diabetes, 6) accidents, 7) suicide, and 
8) unknown or other causes of  death. Death 
from any cardiovascular cause was defined as a 
cardiovascular (ICD 10 I21-25) or cerebrovas-
cular (ICD10 I60-64) cause as the underlying or 
immediate cause of  death. A diabetes-related 
cause was defined as diabetes (ICD10 E10) as 
the underlying or immediate cause of  death. For 
analyses of  mortality in Study IV, a combined 
end-point of  cardiovascular and diabetes-relat-
ed mortality was used. 
Assays
Blood samples were drawn and analyzed for lip-
ids and lipoproteins, HbA1c, and creatinine, as 
well as for genetic analyses. A 24-hour urine col-
lection was performed to determine the urinary 
albumin excretion rate. The classification of  
renal disease was based on local measurements 
of  urinary albumin excretion rate in two of  the 
three overnight or 24-hour urine collections (see 
classification in the beginning of  Section 5).
Lipids and lipoproteins 
Serum lipids and lipoproteins were measured 
at the research laboratory of  Professor Marja-
Riitta Taskinen, Department of  Medicine, Divi-
sion of  Cardiology, Helsinki University Central 
Hospital, Helsinki, Finland. Serum total cho-
lesterol concentrations were determined by en-
zymatic colorimetric assays (ABX Diagnostics, 
HORIBA ABX, Montpellier, France) until Jan-
uary 2006, and thereafter by enzymatic determi-
nation using a Konelab 60i analyzer (Thermo 
Fisher Scientific Inc., Waltham, MA, USA). Se-
rum LDL-cholesterol was calculated using the 
Friedewald formula [316]: 
Serum HDL-cholesterol concentrations were 
measured with a enzymatic colorimetric test us-
ing a HTS 7000 plus Bio Assay Reader (Perkin 
Elmer Inc., Waltham, MA, USA). Serum trig-
lyceride concentrations were determined by en-
zymatic methods (ABX Diagnostics, HORIBA 
ABX, Montpellier, France) until January 2006, 
and thereafter by enzymatic determination us-
ing a Konelab 60i analyzer (Thermo Fisher Sci-
entific Inc., Waltham, MA, USA).
HbA1c
HbA1c was determined by standardized assays 
at each center. In 75% of  the local laboratories, 
the normal nondiabetic range for HbA1c was 
4.0-6.0%. In all centers, the upper normal limit 
was below 7.0%.
Creatinine
Serum creatinine was determined at a central 
laboratory by a kinetic Jaffe reaction using a 
Hitachi 911 E analyzer (Boehringer Mannheim, 
Mannheim, Germany), with normal reference 
for males of  <115 μmol/l and for females 
<100 μmol/l, until January 2002, and thereaf-
ter by a photometric, enzymatic method using 
a Hitachi 917 or Modular analyzer (Boehringer 
Mannheim/Roche Diagnostics, Basel, Switzer-
land), with a normal reference for males of  50-
95 μmol/l and for females 40-90 μmol/l. The 
correlation coefficient between the two meth-
ods was 0.988.
Urinary albumin excretion rate
Urinary albumin was determined at a central 
laboratory by radioimmunoassay using a LKB 
Wallac RiaGamma counter (Pharmacia, Upp-
sala, Sweden) until November 2002, and there-
after by an immunoturbidimetric method us-
ing a Hitachi 911 analyzer (Roche Diagnostics, 
Hoffman-La Roche, Basel, Switzerland). 
HLA genotyping
DNA was extracted from whole blood accord-
ing to standard protocols. In Study II, HLA 
genotyping was performed in a random set of  
1,136 patients, including 63% of  those with a 
positive and 60% of  those with a negative pa-
39Statistical methods38 5 METHODS
rental history of  type 2 diabetes. The HLA geno-
typing was performed in collaboration with the 
research team of  Professor Jorma Ilonen, Im-
munogenetics Laboratory, University of  Turku, 
Turku, Finland. HLA DQA1-DQB1 genotypes 
and DRB1*04 subtypes were identified using 
PCR-based lanthanide-labeled oligonucleotide 
hybridization and time-resolved fluorometry 
detection. In case the differentiation was insuf-
ficient, fluorescence-based automated DNA 
sequencing according to the manufacturer’s in-
structions (MegaBace 1000, Amersham Biosci-
ences, CA, USA) was performed. 
HLA genotypes were divided into five risk cate-
gories based on their risk association with type 1 
diabetes, and the observed genotype frequencies 
in 622 diabetic children and 622 affected family-
based artificial controls in a Finnish population 
[24,317]. Genotypes positive for both DR3 and 
DR4 haplotypes [(DR3)-DQA1*05-DQB1*02/
DRB1*0401/2/4/5-DQA1*03-DQB1*0302] 
were defined as having the highest risk. 
Moderate risk genotypes included those ho-
mozygous for either DR3 or DR4 risk hap-
lotypes, as well as genotypes composed of  
DR4 risk haplotypes and neutral haplotypes, 
or the combination of  DR3 and DR9 haplo-
types (DR3)-DQA1*05-DQB1*02/(DR9)-
DQA1*03-DQB1*0303. 
Other combinations of  DR3 risk haplotype and 
a neutral one were defined as having a slightly 
increased risk. The particular combinations of  
weakly protective (DR13)-DQB1*0603 with 
strong DR4 risk haplotypes (DRB1*0401/2/5)-
DQA1*03-DQB1*0302 were also included in 
this category based on observed frequencies. 
Other genotypes with a combination of  risk-





fined as low-risk genotypes, and those with pro-
tective genotypes associated with neutral hap-
lotypes or genotypes combining two protective 
haplotypes were classified as protective. 
Replication in the DCCT (Study II)
In Study II, the publicly available database of  
the DCCT was used to replicate our findings. 
The database is available at http://www.gcrc.
umn.edu/gcrc/downloads/dcct.html. The 
same criteria as for Study II were used for selec-
tion of  patients from the database, that is adult 
patients with type 1 diabetes with an onset of  
diabetes before 35 years of  age (n = 1,197). In 
the DCCT, a family history of  type 2 diabetes 
was defined as a first-degree relative with type 
2 diabetes [62], and 119 patients (10%) had a 
positive family history.
Statistical methods
The statistical significance of  a difference in 
categorical variables between groups was tested 
with χ2-test. To assess the trend in proportions 
over categories χ2-test for trend analysis was used 
[318] (Study I). In 2x2 tables, a Mantel-Haenszel 
analysis was performed to adjust for age by di-
viding age into quartiles (Study I). Continuous 
variables with a normal distribution were ana-
lyzed with a t-test if  two groups or ANOVA if  
more than two groups were compared (results 
are presented as means with standard devia-
tions). Nonnormally distributed variables were 
analyzed with Mann-Whitney U-test if  two 
groups and with Kruskal-Wallis H-test if  more 
than two groups were compared (presented as 
medians with interquartile ranges). A P value 
<0.05 was considered statistically significant. 
Study I
Logistic regression analyses were used to assess 
the association of  diabetic nephropathy with 
different familial factors and risk scores. The 
models were adjusted for sex, duration of  dia-
betes, and HbA1c. Results are presented as odds 
ratios with 95% confidence intervals. Mortality 
was evaluated with Kaplan-Meier survival analy-
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sis and statistical significance of  differences was 
determined with Log rank test. In the analyses 
for cardiovascular mortality, only cases with 
known cause of  death were included. All analy-
ses were performed using SPSS 12.0.1 statistical 
software (SPSS Inc., Chicago, IL, USA). 
Study II
Logistic regression analyses were used to test 
which variables were independently associated 
with a parental history of  type 2 diabetes. Vari-
ables were included in multivariate models if  P 
<0.05 in the univariate analyses. Results are pre-
sented as odds ratios with 95% confidence in-
terval. All analyses were performed using SPSS 
15.0 statistical software (SPSS Inc., Chicago, IL, 
USA). 
Study III 
Logistic regression analysis was performed to 
assess the independent association of  the meta-
bolic syndrome and its components with dia-
betic nephropathy (vs. normal urinary albumin 
excretion). The multivariate model was adjusted 
for age, sex, HbA1c, and smoking. The data are 
presented as odds ratio with 95% confidence in-
tervals. All analyses were performed using SPSS 
11.5 statistical software (SPSS Inc., Chicago, IL, 
USA). 
Study IV
Separate Cox proportional hazard models were 
used for each of  the definitions of  the meta-
bolic syndrome. The results are presented as 
hazard ratios with 95% confidence intervals. 
Follow-up time to the event studied was used as 
the time variable in the models. For analyses of  
the cardiovascular end-points, the models were 
first adjusted for traditional risk factors (gender, 
age, smoking, LDL-cholesterol, and HbA1c), 
then for previous events, and finally for dia-
betic nephropathy. The Cox regression analyses 
for progression of  renal disease were adjusted 
for duration of  diabetes, gender, smoking, and 
HbA1c. For subanalyses of  the components of  
the metabolic syndrome, the components of  
one definition were analyzed in one model. To 
test the combined effect of  the MSNCEP/MSIDF 
and albuminuria on new cardiovascular events 
and mortality, Kaplan-Meier survival analyses 
were used and statistical significance of  differ-
ences was tested with Log rank test. All analyses 
were performed using SPSS 15.0 statistical soft-
ware (SPSS Inc., Chicago, IL, USA). 
Table 6. Available parental data for patients with and 







Mat. HT (%) 89 90 0.431
Mat. diabetes (%) 92 92 0.462
Mat. CVD (%) 86 88 0.314
Mat. mortality (%) 100 100 -
Pat. HT (%) 80 82 0.233
Pat. diabetes (%) 94 94 0.854
Pat. CVD (%) 81 83 0.181
Pat. mortality (%) 100 100 -
Data are percentages. DN = diabetic nephropathy, Mat. 
= maternal, Pat. = paternal, HT = hypertension, CVD = 
cardiovascular disease.
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Study I - Parental risk factors for 
nephropathy in type 1 diabetes
Parental factors associated with diabetic neph-
ropathy were studied in 2,355 patients with 
type 1 diabetes. Clinical characteristics of  the 
patients are shown in Table 3 (Section 4). Com-
pared with patients without diabetic nephropa-
thy, patients with diabetic nephropathy were 
older, had an earlier onset of  diabetes, a longer 
duration of  diabetes, higher blood pressure, and 
higher HbA1c, as well as a lower estimated glu-
cose disposal rate and glomerular filtration rate. 
Patients with diabetic nephropathy also had 
more coronary heart disease, stroke, and ampu-
tations. Both patients with diabetic nephropathy 
and their parents were older than patients with-
out diabetic nephropathy and their parents, and 
therefore, the results have been adjusted for the 
patients’ age.
Parental risk factors
The availability of  parental data varied between 
82% and 94% for maternal and paternal hyper-
tension, cardiovascular disease, diabetes, and 
mortality. No difference was present in the data 
available for those with and without diabetic 
nephropathy (Table 6) (previously unpublished 
data). Of  the parental factors, only hypertension 
and type 1 diabetes, especially in mothers, were 
independently associated with diabetic neph-
ropathy in patients with type 1 diabetes, after 
adjustment for other parental risk factors, dura-
tion of  diabetes, HbA1c, and gender (Figure 4). 
Clustering of parental risk factors
Figure 5 shows how the prevalence of  diabetic 
nephropathy increased with the load of  hyper-
tension, cardiovascular disease, and diabetes, 
although the data did not reach statistical sig-
nificance for diabetes. If  both, compared with 
neither, of  the parents had hypertension, the 
adjusted odds ratio for diabetic nephropathy 
was 1.56 (95% confidence interval 1.13-2.15). A 
combination of  parental risk factors increased 
the likelihood of  developing diabetic nephropa-
thy. The odds ratios of  the parental factors for 
diabetic nephropathy, adjusted for duration of  
diabetes, gender, and HbA1c, are shown in Table 
7.
Parental mortality
Of  the 4,676 parents, 1,635 (35%) had died. 
The number of  deceased mothers was 584; 
187 (32%) died from cardiovascular disease, 
148 (25%) from cancer, 129 (22%) from other 
causes, and for 120 mothers (21%) the cause 
of  death was unknown. Of  the 1,051 deceased 
fathers, 409 (39%) died from cardiovascular dis-
ease, 213 (20%) from cancer, 232 (22%) from 
other causes, and for 197 (19%) the cause of  
death was unknown. In Kaplan-Meier survival 
analysis, fathers of  patients with diabetic neph-
ropathy showed reduced overall survival (P 
= 0.037) and also reduced survival from fatal 
cardiovascular events (Figure 6). Kaplan-Meier 
curves showed no difference in maternal overall 
survival (P = 0.808) or survival from fatal car-
diovascular events (P = 0.662).
Parental hypertension
OR 1.28 (1.02-1.62), P = 0.037
Maternal hypertension
OR 1.49 (1.17-1.91), P = 0.001
Parental type 1 diabetes
OR 2.60 (1.40-4.80), P = 0.002
Maternal type 1 diabetes
OR 4.32 (1.34-13.94), P = 0.014
Patients with type 1 diabetes 
and diabetic nephropathy
n = 780
Figure 4. Parental factors independently associated with diabetic nephropathy, after adjustment for duration of dia-
betes, HbA1c, and gender. Parental type 2 diabetes, cardiovascular disease, and mortality were not independently 
associated with diabetic nephropathy.




One parent vs. neither parent 1.13 (0.90-1.41) 0.302
Both parents vs. neither parent 1.56 (1.13-2.15) 0.007
Parental diabetes 0.660
One parent vs. neither parent 1.03 (0.83-1.29) 0.765
Both parents vs. neither parent 1.35 (0.69-2.64) 0.376
Parental cardiovascular disease 0.507
One parent vs. neither parent 0.94 (0.74-1.20) 0.637
Both parents vs. neither parent 1.21 (0.81-1.82) 0.349
Parental score of  hypertension and diabetes 0.007
1 vs. 0 points   1.07 (0.84-1.37) 0.567
2 vs. 0 points 1.26 (0.94-1.69) 0.128
3-4 vs. 0 points 2.13 (1.36-3.33) 0.001
Parental score of  hypertension and cardiovascular 
disease 0.099
1 vs. 0 points   0.99 (0.76-1.29) 0.941
2 vs. 0 points 1.23 (0.91-1.67) 0.184
3-4 vs. 0 points 1.48 (1.02-2.13) 0.037
Parental	score	of 	hypertension,	cardiovascular	
disease,	and	diabetes 0.009
1 vs. 0 points    1.09 (0.83-1.45) 0.536
2-3 vs. 0 points 1.15 (0.87-1.53) 0.318
4-6 vs. 0 points 2.13 (1.37-3.33) 0.001
Data are odds ratios with 95% confidence intervals. All parental variables were entered into the logistic regression models as categorical 
variables with 0 points as the reference category. Diabetes = type 1 and type 2 combined. *Adjusted for duration of  diabetes, sex, and 
HbA1c.
41Study I40 6  RESULTS




Figure 5. Frequency of diabetic nephropathy if neither, 
one, or both parents had hypertension (P = 0.001), 
cardiovascular disease (P = 0.006), either type 1 or 
type 2 diabetes (P = 0.075).





















Figure 6. Kaplan-Meier survival analysis of fathers of 
patients with and without diabetic nephropathy, sho-
wing cumulative survival from cardiovascular death (P 
= 0.034).
Study II - Effect of parental type 2 diabe-
tes on patients with type 1 diabetes
The role of  parental history of  type 2 diabetes 
was assessed in 1,860 patients with type 1 dia-
betes. Table 8 shows the clinical characteristics 
of  the patients grouped by parental history of  
type 2 diabetes. Patients with a positive paren-
tal history of  type 2 diabetes had a higher body 
mass index, larger waist circumference, higher 
triglyceride concentrations, and higher HbA1c 
concentrations, while no difference was ob-
served in blood pressure or prevalence of  dia-
betic complications. Surprisingly, patients with a 
positive parental history of  type 2 diabetes had 
a later onset of  type 1 diabetes (Figure 7). This 
association was further evaluated by the use of  
stricter criteria for type 1 diabetes, that is age at 
onset below 25 years (n = 1,465), and the results 
remained unchanged (age at onset 13.3 ± 6.3 vs. 
12.6 ± 6.2 years, P = 0.043), but if  age at onset 
was lowered to 15 years (n = 921) the difference 
in age at onset of  type 1 diabetes disappeared 
(9.0 ± 3.8 vs. 8.8 ± 3.8 years, P = 0.411). The 
publicly available DCCT dataset was used as a 
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replication set, and the results were similar (Fig-
ure 7). The association of  later onset of  type 1 
diabetes with positive family history of  type 2 
diabetes in the DCCT was significant also after 
adjustment for body mass index, triglycerides, 
insulin dose, and HbA1c [odds ratio 1.04 (1.01-
1.07), P = 0.013] (previously unpublished data).
Metabolic syndrome and insulin resistance
The more components of  the MSNCEP that the 
patients fulfilled, the higher the prevalence of  
parental type 2 diabetes (Figure 8). The MSNCEP 
score was associated with parental history of  
type 2 diabetes [5 points vs. 1 point odds ratio 
2.70 (1.51-4.81), P = 0.001, and as a continuous 
score odds ratio 1.16 (1.04-1.28), P = 0.006], 
after adjustment for age at onset of  diabetes, 
HbA1c, and insulin dose. Patients with a positive 
parental history of  type 2 diabetes also had a 
higher insulin dose per body weight (P = 0.008) 
and showed a tendency to be more insulin re-
sistant, defined by a lower estimated glucose 
disposal rate (P = 0.055) (Table 8). Factors in-


































Figure 7. Age at onset of type 1 diabetes in patients with a positive, compared with those with a negative, family 
history of type 2 diabetes in the FinnDiane Study (17.2 ± 9.0 vs. 16.1 ± 8.9, P = 0.008) and in the DCCT cohort 
(23.9 ± 6.5 vs. 22.2 ± 6.8, P = 0.008).
dependently associated with parental history of  
type 2 diabetes are shown in Table 9.
Maternal and paternal history of type 2 diabe-
tes
Patients with a positive maternal history of  type 
2 diabetes were older than those with a nega-
tive parental history, and those with a positive 
paternal history of  type 2 diabetes were notably 
younger (Table 8). Factors independently associ-
ated with a maternal and paternal history of  type 
2 diabetes, after adjustment for age, are shown 
in Table 9. In the logistic regression model for 
maternal history of  type 2 diabetes, estimated 
glucose disposal rate was excluded since waist 
circumference and HbA1c were included in the 
formula for estimated glucose disposal rate. A 
separate analysis was performed with estimated 
glucose disposal rate in the model, while waist 
circumference and HbA1c were excluded, but 
the estimated glucose disposal rate was not in-
dependently associated with maternal history 
of  type 2 diabetes. 
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Table 9. Factors independently associated with parental history of type 2 diabetes as well as with maternal and 
paternal type 2 diabetes
Independent odds ratio 
(95%	CI) P value
Parental history of  type 2 diabetes*
Age at onset of  type 1 diabetes (years) 1.02 (1.01-1.03) 0.004
Body mass index (kg/m2) 1.07 (1.02-1.12) 0.002
Triglycerides (mmol/l) 1.18 (1.03-1.35) 0.016
Insulin dose (IU/kg) 1.63 (1.04-2.54) 0.033
Maternal history of  type 2 diabetes†
Age at onset of  type 1 diabetes (years) 1.02 (1.01-1.03) 0.019
Body mass index (kg/m2) 1.07 (1.02-1.13) 0.013
Triglycerides (mmol/l) 1.18 (1.01-1.38) 0.040
HbA1c (%) 1.11 (1.01-1.22) 0.034
Insulin dose (IU/kg) 1.81 (1.02-3.23) 0.044
Paternal history of  type 2 diabetes‡
Body mass index (kg/m2) 1.05 (1.01-1.09) 0.008
Insulin dose (IU/kg) 1.86 (1.02-3.37) 0.042
Data are odds ratios with 95% confidence intervals. *Model also included waist circumference, HbA1c, and the metabolic syndrome 
according to NCEP definition. †Model also included age, waist circumference, cardiovascular events, and the metabolic syndrome according 
to IDF definition. ‡Model also included age.
HLA haplotypes and genotypes
HLA data were available for 1,136 patients, and 
in these patients 23 different haplotypes were 
found. Haplotypes with a frequency above 
1% are shown in Table 10. The DRB1*0401-
DQB1*0302 and (DR7)-DQA1*0201-
DQB1*02 were slightly more common among 
those with a positive parental history of  type 2 
diabetes, whereas (DR3)-DQA1*05-DQB1*02 
was more common among those with a nega-
tive parental history. These differences were 
not significant after correction for the number 
of  comparisons. The haplotype combinations 
generated 85 different HLA genotypes, and 
these were classified according to the conferred 
risk of  type 1 diabetes. No difference existed 
in frequency with respect to high-, moderate-, 
and low-risk genotypes, or protective genotypes 
in patients with and without a parental history 
of  type 2 diabetes. Genotypes associated with 
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Figure 8. Frequency of parental type 2 diabetes inc-
reased with number of components of the metabo-
lic	 syndrome	 according	 to	 the	 NCEP	 definition	 (P	 =	
0.007).
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Table 11. HLA genotypes by the risk associated with type 1 diabetes grouped by parental history of type 2 diabetes, 































High-risk (%) 28 26 0.522 24 0.312 0.8 <0.001
Moderate-risk (%) 44 48 0.128 45 0.310 11 <0.001
Slightly increased risk (%) 13 8.2 0.028 12 0.077 7.6 0.691
Low-risk (%) 13 13 0.738 17 0.094 32 <0.001
Protective (%) 2.9 3.6 0.543 2.3 0.201 49 <0.001
Data are percentages. *Comparison between negative and positive parental history of  type 2 diabetes. †Comparison between positive 
parental history of  type 2 diabetes and previous results for Finnish children with type 1 diabetes. ‡Comparison between affected family-
based artificial controls and positive parental history of  type 2 diabetes. Copyright © 2009 American Diabetes Association From 
Diabetes Care®, Vol. 32; 2009, 63-68. Reprinted with permission from The American Diabetes Association.
Table 10. Distribution of the most common HLA haplotypes (frequency >1%) in patients with type 1 diabetes and 
available HLA data grouped by parental history of type 2 diabetes (n = 1,136)
Positive parental 








DRB1*0401-DQB1*0302 35 30 0.015
(DR3)-DQA1*05-DQB1*02 20 24 0.033
(DR1/10)-DQB1*0501 12 11 0.290
(DR8)-DQB1*04 7.9 7.8 0.928
DRB1*0404-DQB1*0302 7.7 10 0.059
(DR13)-DQB1*0604 2.8 4.4 0.065
(DR9)-DQA1*03-DQB1*0303 2.6 2.7 0.892
(DR7)-DQA1*0201-DQB1*02 3.6 1.9 0.011
(DR4)-DQA1*03-DQB1*0301 1.9 2.1 0.744
(DR11/12/13)-DQA1*05-DQB1*0301 2.1 1.9 0.841
(DR13)-DQB1*0603 1.8 1.9 0.824
Data are percentages of  the haplotypes in each group. Copyright © 2009 American Diabetes Association From Diabetes Care®, Vol. 
32; 2009, 63-68. Reprinted with permission from The American Diabetes Association.
a slightly increased risk were more common 
among those with a negative parental history 
of  type 2 diabetes. The HLA genotype distribu-
tion in patients with a positive parental history 
of  type 2 diabetes did not differ from a Finn-
ish population of  children with type 1 diabetes, 
but all genotypes, except those that associated 
with a slightly increased risk of  type 1 diabetes, 
differed significantly from a control population 
without diabetes (Table 11).
Study III - The metabolic syndrome in 
type 1 diabetes
The prevalence of  the metabolic syndrome was 
assessed in 2,415 patients with type 1 diabetes. 
Clinical characteristics of  the patients with and 
without the metabolic syndrome are presented 
in Table 4 (Section 4). The prevalence of  the 
MSNCEP and its components by gender and age 
is shown in Tables 12 a-b. Figure 9 shows the 
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MSNCEP (%) 38 40 0.448
MSNCEP obesity (%) 12  20 <0.001
MSNCEP hypertension (%) 76  63 <0.001
MSNCEP low HDL-cholesterol (%) 28  42 <0.001
MSNCEP high triglycerides (%)             24  14 <0.001
Data are percentages










MSNCEP (%) 33 40 41  47 <0.001
MSNCEP obesity (%) 9 15 20  26 <0.001
MSNCEP hypertension (%) 51 69 80  90 <0.001
MSNCEP low HDL-cholesterol (%) 38 37 34  27 0.001
MSNCEP high triglycerides (%) 19 20 19 17 0.753
Lipid-lowering medication (%) 0.8 6.6 14 27 <0.001
Data are percentages
Table 13. Different combinations of the components of 
the MSNCEP in affected patients (n = 944)
Frequency 
(%)	
DM + HT + HDL 30
DM + HT + HDL + trigly 15
DM + HT + obesity 14
DM + HT + trigly 13
DM + HT  + HDL + trigly + obesity 8.4
DM + HT  + HDL + obesity 8.2
DM + HDL + trigly 3.8
DM + HT + trigly + obesity 3.6
DM + HDL + obesity 2.5
DM + HDL + trigly + obesity 0.6
DM + trigly + obesity 0.4
Data are percentages. DM = diabetes, HT = hypertension, 
HDL = low HDL-cholesterol, trigly = high triglycerides
1 2 3 4 5






Figure 9. Distribution of the number of components of 
the	metabolic	syndrome	(NCEP)	fulfilled	by	the	patients	
with type 1 diabetes (n = 2,415).
distribution of  the number of  components ful-
filled by the patients, and the different combina-
tions of  the components are displayed in Table 
13.
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Diabetic nephropathy and the metabolic syn-
drome
Patients with the metabolic syndrome had more 
microvascular complications, including laser-
treated retinopathy and nephropathy (Table 
4). The prevalence of  the metabolic syndrome 
increased with worsening renal disease (Table 
14). After adjustment for age, gender, smok-
ing, and HbA1c, patients with the metabolic 
syndrome, compared with those without, had 
a 3.75-fold (2.89-4.85) increased odds ratio for 
diabetic nephropathy. Of  the individual com-
ponents, hypertension was by far the compo-
nent associated with the strongest relationship 
with diabetic nephropathy [odds ratio 35.75 
(18.33-69.70)], but all other components were 
also independently associated with diabetic 
nephropathy: low HDL-cholesterol [odds ratio 
1.73 (1.39-2.15)], high triglycerides [2.04 (1.60-
2.60)], and abdominal obesity [1.38 (1.07-1.79)] 
(unpublished results). Compared with patients 
fulfilling 1 or 2 components, the odds ratio for 
diabetic nephropathy increased for every added 
component: 3 components 2.81 (2.09-3.78), 4 
components 5.09 (3.45-7.50), and all 5 compo-
nents 11.70 (5.74-23.84). 










MSNCEP (%) 28 44 62 68 <0.001
MSNCEP obesity (%) 12 18 23 29 <0.001
MSNCEP hypertension (%) 55 88 98 99 <0.001
MSNCEP low HDL-cholesterol (%) 33 30 46 46 <0.001
MSNCEP high triglycerides (%) 13 19 33 35 <0.001
Data are percentages. UAER = urinary albumin excretion rate, micro = microalbuminuria, macro = macroalbuminuria, ESRD = 
end-stage renal disease.
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MSNCEP (%) 31 36 51 <0.001
MSNCEP obesity (%) 10 16 21 <0.001
MSNCEP hypertension (%) 60 71 76 <0.001
MSNCEP low HDL-cholesterol (%) 34 33 40 0.010
MSNCEP high triglycerides (%) 13 16 28 <0.001
Data are percentages
Figure 11. Frequency of the metabolic syndrome according to glycemic control and different stages of albuminuria. 
UAER = urinary albumin excretion rate. *P <0.001 within the HbA1c groups, †P <0.001 within the groups of albu-
minuria, ‡P <0.05 within the groups of albuminuria.
Effect of renal function and insulin sensitivity
Most patients with type 1 diabetes with normal 
urinary albumin excretion and renal function 
had normal insulin sensitivity. However, pa-
tients with microalbuminuria were more insulin 
resistant, while decreased renal function was a 
conspicuous feature in those with macroalbu-
minuria, suggesting that insulin resistance pre-
cedes the decline in renal function (Figure 10). 
Glycemic control and the metabolic syndrome
The prevalence of  the metabolic syndrome in-
creased with worsening glycemic control (Table 
15). This association was seen in patients with 
normal urinary albumin excretion, macroalbu-
minuria, and end-stage renal disease, but was 
less clear in patients with microalbuminuria 
(Figure 11). 
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     MSWHO  elevated UAER 2.69 (1.95-3.72) <0.001 10.32 (6.28-16.96) <0.001
     MSWHO  obesity 1.28 (0.97-1.68) 0.080 1.23 (0.92-1.66) 0.170
     MSWHO  hypertension 1.71 (1.26-2.31) <0.001 1.69 (1.23-2.31) 0.001
     MSWHO  dyslipidemia 1.80 (1.38-2.35) <0.001 2.11 (1.60-2.78) <0.001
MSNCEP
     MSNCEP  obesity 0.94 (0.68-1.30) 0.722 0.99 (0.71-1.37) 0.938
     MSNCEP  hypertension 2.00 (1.36-2.39) <0.001 2.04 (1.37-3.04) <0.001
     MSNCEP  low HDL-cholesterol 1.35 (1.03-1.78) 0.031 1.43 (1.07-1.91) 0.016
     MSNCEP  high triglycerides 1.83 (1.35-2.48) <0.001 2.29 (1.68-3.12) <0.001
 MSIDF
     MSIDF  obesity 0.82 (0.63-1.06) 0.132 0.84 (0.63-1.11) 0.212
     MSIDF  hypertension 4.25 (2.28-7.92) <0.001 5.47 (2.66-11.26) <0.001
     MSIDF  low HDL-cholesterol 1.63 (1.24-2.13) <0.001 1.47 (1.10-1.96) 0.009
     MSIDF  high triglycerides 1.76 (1.31-2.37) <0.001 2.32 (1.70-3.15) <0.001
Data are hazard ratios with 95% confidence intervals. *Adjusted for age, gender, smoking, LDL-cholesterol, and HbA1c. MS
WHO 
= metabolic syndrome according to World Health Organization, UAER = urinary albumin excretion rate, MSNCEP = National 
Cholesterol Education Program Adult Treatment Panel III, MSIDF = International Diabetes Federation
Figure	12.	Overlap	between	the	different	definitions	of	
the metabolic syndrome. Copyright © 2009 American 
Diabetes Association From Diabetes Care®, Vol. 32; 
2009, 950-952. Reprinted with permission from The 
American Diabetes Association.
Study IV - The metabolic syndrome as 
a predictor for diabetic complications in 
type 1 diabetes
The predictive role of  the metabolic syndrome 
was assessed in 3,783 patients with type 1 dia-
betes. The metabolic syndrome was assessed 
according to the MSWHO, MSNCEP, and MSIDF. 
Detailed clinical characteristics of  the patients 
are presented in Table 5 (Section 4). The over-
lap between the different definitions is shown in 
Figure 12. Presence of  the MSWHO was observed 
in 44%, MSNCEP in 35%, and MSIDF in 36% of  
the patients.
Cardiovascular events
The median follow-up time was 5.5 (interquartile 
range 3.7-6.7) years, and 263 patients suffered a 
cardiovascular event, 106 (40%) of  whom had a 
history of  cardiovascular events. Of  those who 
suffered a new cardiovascular event, 161 had a 
myocardial infarction [31 (19%) with a history 
of  myocardial infarction], and 80 a stroke [12 
(15%) with a history of  stroke]. The predic-
tive value of  MSWHO, MSNCEP, and MSIDF for the 
different cardiovascular outcomes is shown in 
Table 16. Of  the individual components of  the 
metabolic syndrome, all except obesity were in-
dependent predictors of  cardiovascular events 
(Table 17). 
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Table 18. Mortality by different levels of diabetic nephropathy
Mortality	(%)	
Proportion of  deaths from 
cardiovascular or diabetes-
related	causes	(%)
Normal urinary albumin excretion rate 1.5 56
Microalbuminuria 5.9 75
Macroalbuminuria 17 84
End-stage renal disease 51 94
Unclassified renal status 2.8 57
Data are percentages
Mortality
A total of  285 patients died during a median 
follow-up time of  5.7 (4.0-6.9) years. The most 
common cause of  death was from cardiovascu-
lar disease (n = 160, 56%), and altogether 238 
(84%) died from either cardiovascular or diabe-
tes-related causes, while 13 (5%) died from can-
cer, eight (3%) from accidents, six (2%) commit-
ted suicide, and 20 (7%) died from unknown or 
other causes. The mortality rate was highest in 
patients with diabetic nephropathy and the pro-
portion of  patients who died from cardiovascu-
lar or diabetes-related causes increased with the 
severity of  renal disease (Table 18). The predic-
tive value of  the metabolic syndrome for cardio-
vascular and diabetes-related mortality is shown 
in Table 16. Of  the individual components of  
the metabolic syndrome, all except obesity were 
independent predictors of  cardiovascular and 
diabetes-related mortality (Table 17). 
Combination of albuminuria with the MSNCEP 
and MSIDF definitions
Since MSWHO, which is the only definition that 
includes microalbuminuria, was the strongest 
Figure 13a. 
Cumulative hazard of cardiovascu-
lar events. MS(NCEP)+ = metabolic 
syndrome	according	to	NCEP	definition,	
UAER+ = urinary albumin excretion 
rate	≥20	μg/min	or	≥30	mg/24h.	Diffe-
rence between MS(NCEP)+ UAER- and 
MS(NCEP)- UAER- P = 0.061, difference 
between all other groups P <0.001. 
Copyright © 2009 American Diabetes 
Association From Diabetes Care®, Vol. 
32; 2009, 950-952. Reprinted with per-
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Figure 13b. 
Cumulative hazard of cardiovascu-
lar and diabetes-related mortality. 
MS(NCEP)+ = metabolic syndrome 
according	 to	 NCEP	 definition,	 UAER+	
=	 urinary	 albumin	 excretion	 rate	 ≥20	
μg/min	 or	 ≥30	 mg/24h.	 Differen-
ce between MS(NCEP)+ UAER- and 
MS(NCEP)- UAER- P = 0.928, difference 
























predictor of  cardiovascular morbidity and car-
diovascular and diabetes-related mortality, the 
role of  albuminuria was further evaluated by 
combining albuminuria (≥20 μg/min or ≥30 
mg/24h) with MSNCEP.  MSNCEP added to the risk 
attributed to albuminuria for both cardiovascu-
lar events (Figure 13a) and cardiovascular and 
diabetes-related mortality (Figure 13b). In those 
with an elevated urinary albumin excretion rate, 
MSNCEP was associated with a 1.44 (1.06-1.96) 
hazard ratio for a new cardiovascular event, af-
ter adjustment for traditional risk factors and 
diabetic nephropathy. Even though very few 
events occurred in those with a normal urinary 
albumin excretion rate, there was still a tenden-
cy towards more cardiovascular events in those 
with the metabolic syndrome (MSNCEP) (Figure 
13a). MSIDF did not add to the risk attributed to 
an elevated urinary albumin excretion rate (P = 
0.175), but in those with a normal urinary al-
bumin excretion rate, MSIDF increased the risk 
for cardiovascular events (P = 0.018). Regard-
ing cardiovascular and diabetes-related mortal-
ity, MSIDF did not alter the risk attributed to an 
elevated or normal urinary albumin excretion 
rate (P = 0.075 and P = 0.794, respectively).
Progression of renal disease
During follow-up, 118 patients with normal uri-
nary albumin excretion at baseline developed 
microalbuminuria, 54 with microalbuminuria 
developed macroalbuminuria, and 130 with 
macroalbuminuria developed end-stage renal 
disease. The hazard ratios of  the metabolic 
syndrome and its components for progression 
of  diabetic nephropathy are presented in Table 
19. MSWHO predicted progression to microalbu-
minuria, while MSNCEP and MSIDF did not, and 
none of  the three definitions predicted progres-
sion to macroalbuminuria. Regarding progres-
sion from macroalbuminuria to end-stage renal 
disease, MSWHO and MSNCEP were both signifi-
cant predictors, while MSIDF seemed to be pro-
tective. The seemingly protective role of  MSIDF 
was largely due to MSIDF obesity, the only one 
of  the components to show a potential protec-
tive role. 
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7 DISCUSSION
Strengths and weaknesses of the studies
All patients in Studies I to IV were part of  the 
FinnDiane Study, a prospective study of  Finn-
ish patients with type 1 diabetes. The study pop-
ulation includes 15 to 20% of  the adult patients 
with type 1 diabetes in Finland, and although 
the study is not population-based, it is fairly 
representative of  patients with type 1 diabetes 
in Finland. The geographical distribution of  the 
patients is similar to that of  the general distri-
bution of  people in Finland (Figure 2). Patients 
with type 1 diabetes are usually followed at hos-
pitals by specialists, such as endocrinologists or 
nephrologists. In recent years, due to lack of  re-
sources, the health care of  many young patients 
without diabetic complications has however, 
been transferred to primary health care units. 
The majority of  the FinnDiane Study centers 
are hospitals, and all central and university hos-
pitals in Finland are part of  the study, while 
only 11% of  the 270 primary health care units 
are taking part in the enrollment of  patients. In 
addition, the FinnDiane Study has had a spe-
cial focus on the enrollment of  patients with 
renal involvement. These facts could result in 
an overrepresentation of  patients with diabetic 
complications in the FinnDiane Study, com-
pared with the general type 1 diabetes popula-
tion in Finland.  
The FinnDiane Study population is undoubted-
ly well characterized regarding medical history 
and the presence of  diabetic complications. At 
the baseline visit, anthropometric data are col-
lected, blood samples drawn, and a urine collec-
tion performed. 
Classification of renal status. The classification 
of  diabetic nephropathy status is based on three 
consecutive timed urine collections and on the 
clinical view of  the patient’s attending physi-
cian, thus representing a robust classification. In 
Study I, patients were classified based on their 
renal status as having or not having diabetic 
nephropathy. Patients without diabetic neph-
ropathy, that is those with a normal albumin ex-
cretion rate, were required to have diabetes for 
more than 15 years to ensure normal renal sta-
tus. Since the incidence peak of  diabetic neph-
ropathy occurs 15 to 20 years after the onset 
of  diabetes [7], patients with a shorter duration 
may still develop diabetic nephropathy later. 
One could argue that a bias occurs in requiring 
a limit in one group, but not in the other; how-
ever, only 11 patients with diabetic nephropathy 
had diabetes duration of  less than 15 years. The 
same cut-off  of  diabetes duration of  15 years is 
used in many genetic studies to classify patients 
as having normal renal status [137]. Regarding 
the classification of  diabetic nephropathy, overt 
disease was required, with either end-stage renal 
disease or urinary albumin excretion rate in the 
macroalbuminuria range. 
Classification of other diabetic complications. 
The classification of  diabetic retinopathy is not 
as exact as for nephropathy, being based solely 
on the information of  whether or not retinal 
laser treatment has been performed. This does 
not reveal the severity of  the disease or whether 
the laser treatment has been performed due to 
proliferative retinopathy or to macular edema. 
The data have, however, been validated in a 
subset of  patients with more accurate ophthal-
mic data available, and in 85% the laser treat-
ment was performed because of  proliferative 
retinopathy (based on personal communication 
with Kustaa Hietala). Regarding cardiovascular 
disease, the events were verified from medical 
files and included clinically verified myocardial 
infarction and stroke, as well as history of  coro-
nary revascularization and amputations. Re-
garding the diagnosis of  coronary heart disease, 
pharmacological treatment with long-acting ni-
troglycerin was also included in the definition, 
and thus, this definition may be considered less 
specific.
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Definition of the metabolic syndrome. None of  
the current definitions available for the meta-
bolic syndrome have taken into consideration 
patients with type 1 diabetes. The most widely 
used definitions at the time of  Study III were 
MSWHO and MSNCEP [245,247]. We chose to use 
the MSNCEP when we introduced the concept of  
the metabolic syndrome in patients with type 1 
diabetes, since MSWHO already includes albumin-
uria as one of  the components. We argued that 
the combination of  albuminuria, hypertension, 
and diabetes (= diabetic nephropathy) would al-
ready result in a diagnosis of  the syndrome, and 
since the aim of  Study III was to assess the as-
sociation between the metabolic syndrome and 
diabetic nephropathy, the task would have been 
difficult using the MSWHO definition. The MSIDF 
was introduced in 2005 [249], and thus also 
used in the Study IV, along with MSNCEP and the 
MSWHO, which at that time had also been used 
in other studies on the metabolic syndrome in 
patients with type 1 diabetes [319-321]. All pa-
tients with type 1 diabetes were considered to 
fulfill the criteria for hyperglycemia, consistent 
with earlier studies of  type 2 diabetes [16].
Insulin sensitivity. A direct measure of  insulin 
sensitivity by the euglycemic hyperinsulinemic 
clamp technique would have been the most ac-
curate way of  measuring insulin sensitivity. This 
was, however, not feasible in this large study co-
hort, and thus, an estimation of  the glucose dis-
posal rate was used [179]. This estimation was 
originally validated in 24 patients with type 1 
diabetes, only 5 of  whom had antihypertensive 
medication. How well this formula correlates 
with insulin sensitivity in patients with diabetic 
nephropathy is unknown, but to date the esti-
mated glucose disposal rate is the only available 
estimate of  insulin resistance in patients with 
type 1 diabetes. 
Parental data. In Studies I and II, information 
on parents was received from the patients with 
type 1 diabetes through a questionnaire, and not 
directly from the parents themselves. An op-
timal approach would of  course have been to 
study all parents as well, but this was not fea-
sible in this large cohort. The parental data was, 
however, validated, and showed a 83% sensitiv-
ity in detecting parental hypertension, diabetes, 
and cardiovascular disease. Additional limita-
tions were that parental data in Study I were 
not complete and less information was available 
on deceased parents. Another issue with regard 
to parental data is undiagnosed type 2 diabetes, 
which European studies have shown to account 
for approximately 50% of  all diabetes [1]. Since 
the parents were not themselves studied, we had 
no means of  detecting undiagnosed type 2 dia-
betes in these individuals.
Matching for age. In Study II, assessment of  the 
effect of  parental history of  type 2 diabetes on 
the patients with type 1 diabetes was performed 
in a subset of  age-matched patients. Matching 
of  the population for age was favored due to 
the large age difference between those with and 
those without a parental history of  type 2 diabe-
tes [43.9 ± 10.2 (n = 620) vs. 36.0 ± 11.5 years (n 
= 2,417)]. With such a large age difference, ad-
justment for age in the statistical analyses would 
likely not have entirely compensated the bio-
logical difference between the groups. Post-hoc 
analyses were performed with the entire study 
population, but with such a large age difference, 
the univariate results were unclear. More posi-
tive associations were found, and for the results 
presented in Table 8, after simple age adjust-
ment, all continuous variables were significant 
(P <0.001). Importantly, despite the differences 
in univariate analyses, the results in multivariate 
analyses would largely have been the same, with 
triglycerides 1.16 (1.03-1.30), body mass in-
dex 1.05 (1.02-1.08), and age of  diabetes onset 
1.01 (1.01-1.03) independently associated with 
parental history of  type 2 diabetes. Compared 
with the matched population, only the insulin 
dose per body weight, a surrogate marker of  
insulin sensitivity, would not have remained in 
the model.
Follow-up data. Follow-up data have been col-
lected in the FinnDiane Study since 2004, and 
is ongoing with the goal to re-examining all 
patients who have participated in phase I. In 
57Parental risk factors56 7 DISCUSSION
Studies I to III, prospective data were not yet 
available, and thus the studies represent only 
cross-sectional data. In Study IV prospective 
data were, however, available and used. The fol-
low-up data are complete regarding mortality, 
and these data are based on death certificates, 
which is the method of  choice. Regarding data 
on cardiovascular and renal morbidity, the col-
lection of  follow-up data is ongoing. Thus, in 
Study IV, follow-up data on cardiovascular and/
or renal morbidity were available for only a sub-
set of  69% of  the patients. The morbidity data 
were based on a follow-up visit that included a 
thorough clinical examination for 36% of  the 
patients, whereas the data were based on review 
of  medical files for 64% of  the patients. The 
review of  medical files is done one study center 
at a time, thus including complete data for each 
study center, diminishing the bias related to the 
collection of  follow-up data. Generally, patients 
for whom we lack follow-up data on morbidity 
are those who participated in phase I at a later 
stage, and due to a rather short follow-up time, 
will be restudied later. No difference was pres-
ent in gender, age, or duration of  diabetes in 
those with and without available data on mor-
bidity at follow-up. However, those without 
follow-up data have a somewhat lower preva-
lence of  diabetic complications, such as diabetic 
nephropathy, retinal laser treatment, and cardio-
vascular events, as well as a lower prevalence of  
the metabolic syndrome according to MSWHO 
and MSNCEP, but not MSIDF. It is noteworthy that 
although morbidity data were available for only 
69% of  the patients, a significant number of  
cardiovascular events occurred in these patients 
during the 5.5-year follow-up, highlighting the 
clinical relevance of  these data. 
Which parental factors play a role in dia-
betic nephropathy? 
In Study I, parental risk factors for diabetic 
nephropathy were assessed in a large cohort of  
patients with type 1 diabetes. Results showed 
that parental factors play a role in diabetic 
nephropathy. Notably, parental hypertension 
was the factor most strongly associated with 
diabetic nephropathy, while neither parental 
cardiovascular disease nor type 2 diabetes was 
not independently associated, but a cluster of  
all these traits was significantly associated with 
nephropathy. 
The association between parental hypertension 
and diabetic nephropathy was driven by mater-
nal hypertension. Although paternal hyperten-
sion was not independently associated with dia-
betic nephropathy, the association was stronger 
if  both parents had hypertension. Viberti et al. 
were the first to show higher blood pressure 
in parents of  17 patients with type 1 diabetes 
and proteinuria, compared with 17 patients 
with normal albumin excretion rate [110]. As 
seen in Table 1, several studies have replicated 
this finding [111-119], although no association 
has also been observed in some large studies 
[121,122,124]. Only one small study assessed 
the separate role of  maternal and paternal his-
tory of  hypertension and reported higher blood 
pressure in mothers of  patients with diabetic 
nephropathy [130]. In Study I, hypertension 
was the strongest of  the parental risk factors, 
suggesting that a genetic predisposition to hy-
pertension is important in the pathogenesis of  
diabetic nephropathy.
Parental type 1 diabetes was also independently 
associated with diabetic nephropathy, and this 
novel finding has not been reported in other 
studies. The prevalence of  type 1 diabetes was, 
however, rather low. Rudberg et al. showed no 
association between parental type 1 diabetes and 
microalbuminuria in patients with type 1 diabe-
tes [117], and Monti et al. more recently also 
failed to find any association between parental 
type 1 diabetes and self-reported diabetic neph-
ropathy in a large study of  patients with type 1 
diabetes [322]. One explanation for the discrep-
ant results could be the different methodolo-
gies applied. This is true for both the definition 
of  diabetic nephropathy and the definition of  
type 1 diabetes in parents. Rudberg et al. defined 
nephropathy as a urinary albumin excretion rate 
of  ≥15 μg/min, which means microalbuminuria 
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or high normal albumin excretion, and found 
through a questionnaire a high prevalence of  
type 1 diabetes in parents (11%). Monti et al. 
had a large data set with much missing data, and 
the parental information was received by ques-
tionnaire as well. In Study I, we were unable to 
classify the type of  parental diabetes in 12% of  
parents with diabetes. The other two studies do 
not report how they classified the type of  dia-
betes in the parents. Another issue is that none 
of  these three studies had information on the 
nephropathy status in parents with type 1 diabe-
tes, and thus, it cannot be ruled out that the as-
sociation with parental type 1 diabetes is driven 
by parental diabetic nephropathy. 
Parental cardiovascular morbidity was not inde-
pendently associated with diabetic nephropathy. 
This is in line with other studies that observed 
no association between nephropathy and mor-
bidity alone, but detected an association using 
a combined end-point of  cardiovascular mor-
bidity and mortality [114,125]. In our study, pa-
rental mortality from cardiovascular disease was 
associated with diabetic nephropathy, especially 
in fathers.  
Previous studies have shown contradictory re-
sults regarding the association between parental 
type 2 diabetes and diabetic nephropathy [114-
118,120,123,127,128], but two more recent 
large-scale studies have revealed associations 
between nephropathy and parental type 2 dia-
betes [124,322]. Although parental type 2 diabe-
tes per se was not independently associated with 
diabetic nephropathy in our study, the cluster 
of  hypertension, type 2 diabetes, and cardio-
vascular disease was associated with a higher 
risk of  nephropathy. This could indicate that a 
common factor behind these three entities, for 
example insulin resistance, might be of  greater 
importance than hypertension, cardiovascular 
disease, and diabetes alone.
Overall, the associations between parental fac-
tors and diabetic nephropathy in Study I were 
less pronounced than in some studies from the 
late 1980’s and the beginning of  the 1990’s. One 
explanation is that treatment could affect the 
phenotypes of  both the patients with diabetes 
as well as their parents. Over the last decade, 
treatment of  patients with diabetic nephropa-
thy has improved, and along with this also the 
prognosis of  patients [78]. Patients with dia-
betes are treated with renoprotective agents 
to postpone or even prevent the development 
of  diabetic nephropathy, an action that might 
result in patients with a genetic predisposition 
to diabetic nephropathy to remain in the group 
of  patients without diabetic nephropathy. The 
worldwide obesity epidemic and the subsequent 
increase in the incidence and prevalence of  type 
2 diabetes [323], could also dilute the parental 
data, such that the type 2 diabetes observed in 
parents today may be due to genes to a lesser 
degree and to environmental factors to a higher 
degree. Since no clear association between pa-
rental type 2 diabetes and diabetic nephropathy 
was observed, the significance of  parental his-
tory of  type 2 diabetes for the patient with type 
1 diabetes was further explored in Study II.
What is the consequence of family history 
of type 2 diabetes for patients with type 
1 diabetes? 
Little is known about the consequence of  pa-
rental history of  type 2 diabetes for patients 
with type 1 diabetes. This issue was addressed 
in Study II, where the impact of  parental his-
tory of  type 2 diabetes was assessed in a cohort 
of  patients with type 1 diabetes, matched for 
age and gender. Parental history of  type 2 dia-
betes was associated with a later onset of  type 
1 diabetes, a higher prevalence of  the metabolic 
syndrome, and a metabolic profile related to in-
sulin resistance.
In patients with, compared with those without, 
a parental history of  type 2 diabetes, the finding 
of  a later onset of  type 1 diabetes was surpris-
ing, given the similar distribution of  high-risk 
HLA genotypes in these two patient groups. 
High-risk HLA genotypes explain a substantial 
proportion of  the genetic predisposition to type 
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1 diabetes and are rarely seen in patients with 
type 2 diabetes [324]. The distribution of  HLA 
genotypes observed in Study II is also similar 
to the Finnish pediatric reference population 
shown in Table 11, and speaks in favor of  a 
true type 1 diabetes population. With equal ge-
netic predisposition, one would, in line with the 
accelerator hypothesis, expect that patients with a 
parental history of  type 2 diabetes would have 
an increased risk of  accelerated loss of  β-cell 
function, and consequently, a lower age at onset 
of  type 1 diabetes. In nondiabetic offspring, a 
parental history of  type 2 diabetes results in in-
sulin resistance and a higher prevalence of  obe-
sity [11,12], factors that in the accelerator hypoth-
esis are assumed to be the underlying cause for 
accelerated β-cell loss. Notably, the association 
between parental history of  type 2 diabetes and 
later onset of  type 1 diabetes was replicated in 
the DCCT, which strengthens the observation, 
although it seems to be confined to patients 
with age at onset above 15 years.
Furthermore, in Study II, patients with a posi-
tive parental history of  type 2 diabetes had a 
higher body mass index, larger waist circumfer-
ence, higher triglyceride concentration, mar-
ginally higher HbA1c, and higher insulin dose 
per body weight. Of  these, body mass index, 
triglycerides, and insulin dose per body weight 
showed independent relationships with paren-
tal type 2 diabetes, reflecting a worse metabolic 
profile and suggesting the presence of  insulin 
resistance. Other studies with the same design 
are not available, and it is of  note that previ-
ous studies have mainly addressed the role of  
parental type 2 diabetes with respect to the 
presence of  diabetic complications. They have 
furthermore only reported univariate data and 
in a descriptive manner. In these studies, a pa-
rental history of  type 2 diabetes was associated 
with various lipid disturbances [62,128], while 
results regarding other metabolic variables, such 
as glycemic control, insulin dose, hypertension, 
and obesity, have shown conflicting results 
[62,116,118,128,325]. 
In type 2 diabetes, an excessive maternal trans-
mission of  diabetes occurs, and the effect on 
the metabolic profile of  offspring without dia-
betes seems to be worse if  the mother, rather 
than the father, has type 2 diabetes [61]. This 
issue was also addressed in Study II, and the 
results indicated a worse metabolic profile, and 
a higher prevalence of  cardiovascular events in 
those with a history of  maternal type 2 diabe-
tes. There was, however, a more than 5-year age 
difference between those with a history of  ma-
ternal type 2 diabetes and those with a history 
of  paternal diabetes. The biological significance 
of  such a large age difference might not be ap-
propriately controlled for by adjustment for age 
in the statistical analyses, and thus, the results 
should be interpreted with caution. 
What is inherited from parents with type 
2 diabetes? 
Is it insulin resistance or β-cell dysfunction that 
is inherited? Insulin resistance is thought to be 
an underlying condition in type 2 diabetes, while 
β-cell dysfunction is required for the disease to 
manifest. Recent results from genome-wide as-
sociation studies for type 2 diabetes highlight 
the importance of  β-cell dysfunction in the 
pathogenesis of  type 2 diabetes. Most of  the 
genes identified are related to decreased insulin 
secretory capacity and cell-cycle dysregulation 
[326-328]. The gene most strongly associated 
with type 2 diabetes is TCF7L2, a transcription 
factor involved in the Wnt signaling pathway. 
TCF7L2 is thought to be involved in impaired 
insulin secretion, via a decreased stimulatory 
effect of  the incretin hormones, glucagon-like 
peptide-1 and gastric inhibitory polypeptide, on 
insulin secretion [329]. It can be argued that if  
genes involved in β-cell dysfunction are more 
important than genes involved in insulin resis-
tance, one would expect little or no effect of  pa-
rental type 2 diabetes on the metabolic pheno-
type of  patients with type 1 diabetes. Although 
less genes directly involved in insulin resistance 
have been found so far, it is noteworthy that 
insulin resistance clearly clusters in families of  
type 2 diabetes, due to both genetic and envi-
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ronmental factors, such as obesity and a sed-
entary lifestyle [11]. Our study design does not 
provide an answer to whether it is the genetic 
effect or the environmental effect of  parental 
type 2 diabetes that is more important in pa-
tients with type 1 diabetes with regard to meta-
bolic profile or presence of  indicators of  insulin 
resistance. 
One interesting point that may dilute our data is 
that the form of  type 2 diabetes seen in parents 
of  patients with type 1 diabetes might represent 
a different kind of  disease than type 2 diabe-
tes in general. This hypothesis is supported by 
the observation of  a higher proportion of  glu-
tamate decarboxylase antibodies and high-risk 
HLA genotypes in patients with type 2 diabetes 
from families with a mix of  type 1 and type 2 
diabetes [324]. In Study II, we unfortunately did 
not have data on HLA genotypes or glutamate 
decarboxylase antibodies of  the parents.
Does the metabolic syndrome exist in pa-
tients with type 1 diabetes? 
Insulin resistance and many of  the components 
of  the metabolic syndrome per se have been 
implicated in the pathogenesis of  micro- and 
macrovascular complications in type 1 diabetes. 
Thus, the question arises of  whether these com-
ponents cluster in patients with type 1 diabetes 
in a similar fashion as observed in subjects with 
the metabolic syndrome. If  this is true, it would 
imply that the metabolic syndrome is not only 
a phenomenon associated with type 2 diabetes, 
but also with type 1 diabetes. 
Interestingly, in Study III, the metabolic syn-
drome was shown to be a prevalent finding in 
patients with type 1 diabetes. The metabolic syn-
drome was observed in 38% of  male and 40% 
of  female patients. This was the first study to 
report the presence of  the metabolic syndrome 
in patients with type 1 diabetes. The prevalence 
of  the metabolic syndrome increased with age, 
being 33% in patients aged under 30 years and 
47% in those over 50 years. These frequencies 
are clearly higher than in the general population 
in Finland, but lower than in patients with type 
2 diabetes [16].
The metabolic syndrome was also more preva-
lent with worsening glycemic control and with 
worsening renal function. Importantly, the met-
abolic syndrome was associated with a 3.75-fold 
odds ratio for diabetic nephropathy after ad-
justment for traditional risk factors. In patients 
with type 2 diabetes, an association between the 
metabolic syndrome and diabetic nephropathy 
has also been reported. Isomaa et al. showed 
an association between the MSWHO and both 
micro- and macrovascular complications [267]. 
It could be argued that this association would 
be influenced by the inclusion of  albuminuria 
in the MSWHO, but this does not seem to be the 
case since the association with complications 
has also been observed using MSIDF and MSAHA/
NHLBI, neither of  which includes microalbuminu-
ria in the definition of  the metabolic syndrome 
[330-332]. 
Of  the components of  the metabolic syndrome, 
hypertension appears to play a dominant role, 
an observation that is different from that seen 
in subjects without diabetes or with type 2 dia-
betes [16]. Nevertheless, all components of  the 
metabolic syndrome were independently associ-
ated with diabetic nephropathy. Compared with 
patients fulfilling one or two components, each 
additional component further added to the odds 
ratio for diabetic nephropathy. This indicates 
that although hypertension might be important, 
each component play a role.
In Study III, the relationships between albu-
minuria and estimated renal function and be-
tween albuminuria and insulin sesnitivity was 
assessed. It seemed that the decline in insulin 
sensitivity was observed already in patients with 
microalbuminuria, well before the observed de-
cline in renal function. This is in line with many 
previous studies reporting insulin resistance to 
precede or parallel the development of  microal-
buminuria and diabetic nephropathy in patients 
with type 1 diabetes [18,176,177], although 
61The metabolic syndrome60 7 DISCUSSION
some contradictory studies also exist [178]. 
The role of  the metabolic syndrome in patients 
with type 1 diabetes has since our original report 
been evaluated in several other studies summa-
rized in Table 20. The Metascreen Study showed 
that the metabolic syndrome was a common 
finding in an Italian population of  638 patients 
with type 1 diabetes, who had a fairly high age at 
onset of  type 1 diabetes [330]. The prevalence 
of  the metabolic syndrome was 41% and 34% 
with the MSIDF and MSAHA/NHLBI definitions, re-
spectively, and was associated with a 3-fold odds 
ratio for diabetic nephropathy, which is similar 
to that observed in Study III. In our FinnDiane 
Study cohort, the MSNCEP was also associated 
with low physical activity and independently 
associated with laser-treated retinopathy [333]. 
McGill et al. reported in a younger Australian 
cohort a significantly lower prevalence of  the 
metabolic syndrome according to the MSWHO, 
nevertheless, showing an association between 
the metabolic syndrome and diabetic complica-
tions, even in patients with a normal albumin 
excretion rate [320]. In a Hungarian population 
of  similar age to the patients in Study III, the 
metabolic syndrome was observed in one-third 
of  patients [334], and was further associated 
with a lower level of  education [335]. 
In a recent study, presence of  the metabolic 
syndrome in type 1 diabetes was compared with 
that observed in patients with type 2 diabetes, 
LADA, and subjects without diabetes. The met-
abolic syndrome was less common in patients 
with type 1 diabetes (32%), than in those with 
LADA (42%), although markedly more com-
mon in those with type 2 diabetes (89%). If  
glucose was excluded as a component of  the 
metabolic syndrome, there was no excess of  the 
metabolic syndrome in patients with type 1 dia-
betes compared with subjects without diabetes 
[336]. There were, however, rather large age dif-
ferences between the different patient groups in 
this study. Taken together, in patients with type 
1 diabetes, the metabolic syndrome is a com-
mon finding and is associated with micro- and 
macrovascular complications of  diabetes. Thus, 
in answer to the question, the metabolic syn-
drome seems to exist also in patients with type 
1 diabetes, although it is unclear whether the 
metabolic syndrome observed in type 1 diabetes 
is the same as in type 2 diabetes or in the general 
population.
MSIDF identifies a similar proportion of  patients 
as the MSNCEP, although a greater gender differ-
ence is observed for MSIDF, due to more strin-
gent criteria for waist circumference [330,334]. 
In the general population, at least in the United 
States, such a gender difference between the 
two definitions has not been observed [337]. It 
is of  note that in Study II an association be-
tween parental history of  type 2 diabetes and 
the metabolic syndrome in patients with type 1 
diabetes was also detected. This association has 
not been previously reported, although a Ger-
man study found no association between type 2 
diabetes in first-, or second-degree relatives and 
a modified metabolic syndrome in patients with 
type 1 diabetes [338]. 
[339]
Criticism against the existence of the me-
tabolic syndrome 
Recently, the whole concept of  the metabolic 
syndrome has been challenged [340-342]. The 
main criticism does not question the clustering 
of  cardiovascular risk factors, but making or 
not making the diagnosis of  the metabolic syn-
drome. The usefulness of  making the diagno-
sis with regard to clinical practice, research, or 
therapeutic aspects has been questioned. One 
argument has been that the current definitions 
for the metabolic syndrome do not include all 
potential components, but some factors like in-
flammatory markers and fatty liver has been left 
out. Criticism has also been raised because the 
components selected are not based on prospec-
tive follow-up studies, and the cut-off  values 
are chosen arbitrarily. Those skeptical of  the 
use of  the metabolic syndrome further argue 
that the use of  continuous variables would be 
more informative than the use of  dichotomized 
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variables. In addition, the use of  the metabolic 
syndrome as a risk marker for cardiovascular 
disease beyond the risk associated with its in-
dividual components has been criticized. How-
ever, a confirmatory factor analysis supported 
the current clinical definition of  the metabolic 
syndrome as well as the existence of  a single 
factor underlying the metabolic syndrome and 
linking all of  the components together [343]. 
Other confirmatory factor analyses have also 
suggested that a four-factor model including 
the current components of  the syndrome (insu-
lin resistance, obesity, lipids, and hypertension) 
would have the best fit, although not identifying 
an underlying factor [344]. Studies using princi-
pal component analysis have usually generated 
two to four components and found a weaker 
association with the core components and hy-
pertension [345]. 
Those arguing for the existence of  the meta-
bolic syndrome highlight that these cardiovas-
cular risk factors have been shown to cluster 
in several studies, ranging back more than a 
decade, and have repeatedly been associated 
with an increased cardiovascular risk [346]. In 
addition, although all components of  the meta-
bolic syndrome carry an individual risk of  car-
diovascular disease, the concept of  a cluster of  
risk factors, the metabolic syndrome, serves as a 
simple and easily applicable tool in clinical prac-
tice to detect patients at risk of  cardiovascular 
disease and also at risk of  type 2 diabetes [347]. 
The decision to include some of  the compo-
nents in the syndrome, while omitting others, 
was made to ensure that the measurements are 
easily applicable in clinical practice worldwide, 
without making a statement that other compo-
nents are less important in the pathogenesis of  
the syndrome [346]. Importantly, those in favor 
of  the concept of  the metabolic syndrome do 
not deny that the risk related to the syndrome is 
continuous in nature, and that the risk is higher 
the larger the waist circumference, the higher 
the blood pressure, the lower the HDL-choles-
terol, the higher the triglyceride level, the more 
insulin resistant the individual, the more fat ac-
cumulation in the liver, and the higher the C-
reactive protein concentration. Requiring three 
of  the components of  the metabolic syndrome 
for diagnosis does not mean that the risk is zero 
if  two or less of  the components are fulfilled or 
absolute if  three or more components are ful-
filled, but rather that the risk is continuous in 
nature. The more components, the greater the 
risk. And if  one component is found, others 
should be sought.
Which	of	the	current	definitions	is	best	in	
predicting cardiovascular risk in patients 
with type 1 diabetes? 
In Study IV, the predictive role of  the metabolic 
syndrome in cardiovascular events, cardiovascu-
lar and diabetes-related mortality, and progres-
sion of  diabetic nephropathy was assessed. The 
results confirmed earlier findings regarding the 
metabolic syndrome as a predictor of  cardio-
vascular disease and diabetes-related mortality 
in type 1 diabetes. It was evident that the dif-
ferent definitions identified different sets of  
patients, and thus, the predictive value of  the 
definitions varied considerably. The MSWHO was 
the strongest predictor, followed by the MSNCEP, 
while the MSIDF did not predict the studied out-
comes at all. A new finding was that the MSWHO 
was an independent predictor of  cardiovascular 
events and cardiovascular and diabetes-related 
mortality, even after adjustment for diabetic 
nephropathy. It is noteworthy that the MSNCEP 
added to the risk associated with elevated albu-
minuria alone.
The prevalence of  the metabolic syndrome was 
similar using the different definitions, rang-
ing from 35% to 44%, but only 18% fulfilled 
all three definitions. Since the different defini-
tions did not necessarily identify the same pa-
tients, a comparison of  the different definitions 
seems appropriate. In subjects without diabetes, 
the overlap between the different definitions 
is more complete. The MSNCEP and the MSWHO 
classify the subjects identically in 86% of  cases 
[254], and MSNCEP and MSIDF in 93% of  cases 
[337], while in Study IV the corresponding fre-
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quencies were 75% and 73%.
The oldest of  the three definitions, the MSWHO, 
which is the only one that includes microal-
buminuria, was associated with a 2.1-fold in-
creased risk of  cardiovascular events, and a 
2.5-fold increased risk of  cardiovascular and 
diabetes-related mortality after adjustment for 
diabetic nephropathy, and a 2.6-fold increased 
risk of  progression to end-stage renal disease. 
The MSWHO was also associated with a 2.8- and 
3.1-fold increased risk of  stroke and myocardial 
infarction, respectively, an association previous-
ly observed in subjects without diabetes [255]. 
The MSNCEP, which gives equal importance to 
all components, was not an independent predic-
tor after adjustment for diabetic nephropathy, 
although adjustment for traditional risk fac-
tors and previous events resulted in a 1.6-fold 
increased risk of  cardiovascular events and a 
2.2-fold increased risk of  cardiovascular and 
diabetes-related mortality. Notably, these haz-
ard ratios are of  the same magnitude as in the 
general population. The MSIDF, which highlights 
abdominal obesity as the central component, 
was not an independent predictor of  the stud-
ied outcomes.
Our findings support the data from two pro-
spective studies on the role of  the metabolic 
syndrome in type 1 diabetes [321,348], and it 
is obvious that of  the current definitions avail-
able the MSWHO seems to be associated with 
the highest risk of  cardiovascular outcomes. 
Results from the DCCT showed MSIDF to be 
a poor predictor of  micro- and macrovascu-
lar diabetic complications [348]. In their rather 
young patients, the prevalence of  MSIDF was the 
highest among those allocated to the intensively 
treated group. These same patients also gained 
the most weight, but had nevertheless the low-
est risk of  outcomes [144]. This could possibly 
explain the poor predictive value of  the MSIDF 
in the DCCT. In the Pittsburgh Epidemiology 
of  Diabetes Complications Study, with gener-
ally younger patients and less diabetic complica-
tions than in Study IV, the prevalence of  MSWHO, 
MSNCEP, and MSIDF varied between 8% and 21%, 
and the MSWHO was the best predictor of  all out-
comes studied, followed by the MSNCEP, while 
the MSIDF was again associated with the low-
est risk [321]. The authors concluded that the 
individual components, especially albuminuria, 
which reflects generalized vascular damage and 
diabetic nephropathy, predicted the outcomes 
better than the metabolic syndrome itself.  In 
Study IV, the MSWHO, compared with the albu-
minuria component of  the definition, showed 
a higher hazard ratio for cardiovascular events, 
but a lower hazard for cardiovascular and dia-
betes-related mortality. As shown in Study III, 
the prevalence of  the metabolic syndrome in-
creases with worsening renal disease in patients 
with type 1 diabetes, and diabetic nephropathy 
is also the strongest risk factor for cardiovascu-
lar outcomes in patients with type 1 diabetes [5]. 
In Study IV, most of  the cardiovascular events 
were observed in those with diabetic nephropa-
thy, and it is thus difficult to eliminate the ef-
fect of  diabetic nephropathy. The independent 
risk shown for MSWHO in cardiovascular events 
and cardiovascular and diabetes-related mortal-
ity adjusted for diabetic nephropathy suggests, 
however, that the metabolic syndrome indeed 
plays an independent role. Nevertheless, it 
could be argued that the observed effect is due 
to microalbuminuria, which is only included in 
the MSWHO definition. This issue was therefore 
evaluated further, and an additional effect of  the 
MSNCEP beyond albuminuria alone was detected. 
This suggests a true role of  the metabolic syn-
drome as a risk factor for cardiovascular out-
comes and cardiovascular and diabetes-related 
mortality.
The metabolic syndrome is a predictor of  chron-
ic renal disease in the general population [14], 
but although MSNCEP clearly increases in parallel 
with worsening of  renal disease in patients with 
type 1 diabetes, the role of  the metabolic syn-
drome as a risk factor for diabetic nephropathy 
is not straightforward. Results from the DCCT 
showed no effect of  MSIDF on the development 
of  microalbuminuria, and in the Pittsburgh Ep-
idemiology of  Diabetes Complications Study, 
the MSIDF had no effect on the development 
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of  renal failure, while MSWHO and MSNCEP pre-
dicted renal failure. Interestingly, a recent large 
Chinese study in patients with type 2 diabetes 
showed MSNCEP to increase the risk of  chronic 
kidney disease in a 5-year follow-up [349]. In 
Study IV, only the MSWHO predicted the devel-
opment of  microalbuminuria, while none of  
the definitions predicted progression from mi-
croalbuminuria to macroalbuminuria. At a later 
stage of  the disease, both MSWHO and MSNCEP 
predicted progression from macroalbuminuria 
to end-stage renal disease. Taken together, the 
role of  the metabolic syndrome in progression 
to microalbuminuria (incident microalbuminu-
ria) is apparently modest, while at a later stage 
of  the disease, multiple metabolic abnormalities 
increase the risk of  chronic renal disease. 
 
In patients with type 1 diabetes, abdominal obe-
sity seems to be the component of  the meta-
bolic syndrome that has the weakest predictive 
role. This is a somewhat surprising finding since 
abdominal obesity is a key feature of  insulin 
resistance, an established risk factor for car-
diovascular disease [235]. All of  the other indi-
vidual components were, however, independent 
predictors of  both cardiovascular events and 
cardiovascular and diabetes-related mortality. 
Although abdominal obesity was not indepen-
dently associated with the outcomes, it could still 
play a role in the overall syndrome, for example, 
by being a contributing factor. The weak role of  
MSIDF, which highlights obesity as the key fea-
ture, on the other hand indicates that obesity 
plays a minor role. In patients on dialysis, obe-
sity has been associated with better survival (the 
obesity paradox), highlighting the importance 
of  optimal nutrition in such patients [350]. 
In the present study, the MSIDF obesity (waist 
circumference above 80 cm in females and 94 
cm in males) was protective of  development 
of  end-stage renal disease, suggesting that the 
relationship between obesity and development 
of  renal failure might be inverse or u-shaped, at 
least in patients with macroalbuminuria. In pa-
tients with type 1 diabetes, improvement of  gly-
cemic control could lead to an increase in body 
weight [351], and the protective role of  obesity 
observed in Study IV could consequently be 
due to better glycemic control in these patients. 
In Study IV, the patients with macroalbuminuria 
who progressed to end-stage renal disease had, 
however, higher HbA1c and lower insulin dose 
per body weight [352].  
Concluding remarks and future prospects
Figure 14 summarizes the results of  Studies I 
to IV and how the findings relate to each other. 
A strong association was present between the 
metabolic syndrome and diabetic nephropathy, 
but the predictive value of  the metabolic syn-
drome in the development of  diabetic neph-
ropathy was less clear. The observed association 
between diabetic nephropathy and the cluster 
of  parental risk factors suggests that a common 
underlying factor, for example insulin resistance, 
might be of  greater importance than parental 
hypertension, cardiovascular disease, and diabe-
tes in isolation. A genetic predisposition to insu-
lin resistance could also explain the unfavorable 
metabolic profile seen in the patients with type 
1 diabetes and the positive parental history of  
type 2 diabetes. It is noteworthy, that diabetic 
nephropathy and the metabolic syndrome (re-
flecting insulin resistance?) were both indepen-
dent predictors of  cardiovascular morbidity and 
mortality.
Studies I to IV left some questions unanswered, 
and further research is needed to assess the fol-
lowing questions: Do parental risk factors pre-
dict the development of  diabetic nephropathy 
in prospective studies? What is the role of  obe-
sity in the progression of  renal disease? Is there 
a true protective role of  obesity in the progres-
sion to end-stage renal disease? If  so, is the risk 
linear or u-shaped?  
Another important question is whether the 
metabolic syndrome should be defined differ-
ently in patients with type 1 diabetes? And if  
so, should the main target be to find the best 
cardiovascular risk cluster? Or should it be to 
identify the best cluster that brings together and 
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highlights the pathogenetic mechanisms under-
lying the metabolic syndrome (insulin resistance, 
elevated triglycerides, low HDL-cholesterol, hy-
pertension, abdominal obesity, inflammation, 
fatty liver)? Should a simple measure of  insulin 
resistance, like the estimated glucose disposal 
rate or just the insulin dose, be added to the def-
inition instead of  hyperglycemia? It is also not 
known whether abdominal obesity should be 
defined differently. The MSIDF includes abdomi-
nal obesity as a mandatory component, and it is 
important to acknowledge that all patients with 
insulin resistance are not obese [286]. Thus, re-
quiring obesity in the definition might result in 
some subjects at risk being missed, as shown 
in the Diabetes Epidemiology: Collaborative 
Analysis of  Diagnostic Criteria in Europe Study 
[353]. In addition, the cut-off  value for waist 
circumference for females in the MSIDF seems 
to lead to an overrepresentation of  females with 
the metabolic syndrome in patients with type 1 
diabetes, a phenomenon not observed in sub-
jects without diabetes [337]. 
Another question is whether or not albuminuria 
should be included in the definition. In patients 
with diabetes, albuminuria usually reflects the 
presence of  diabetic nephropathy (which seems 
to be an insulin resistant state), although the ini-
tial idea behind the inclusion of  albuminuria in 
the definition was that it reflects a generalized 
vascular damage and endothelial dysfunction 
associated with insulin resistance. 
Does recognition of  the metabolic syndrome 
in patients with type 1 diabetes call for spe-
cific attention regarding their treatment? In the 
treatment, it is of  course important to focus 
on diet, exercise, and weight loss, in addition 
to the use of  cardio- and renoprotective agents 
to control blood pressure and dyslipidemia. 
Could oral hypoglycemic agents be beneficial in 
the treatment of  overweight and insulin resis-
tant patients with type 1 diabetes? One of  the 
most frequently used oral hypoglycemic agents 
in overweight patients with type 2 diabetes is 
metformin, which enhances glycemic control 
through improvement of  the actions of  insulin 
in muscle and liver. The use of  metformin is 
contraindicated in patients with kidney disease 
due to an increased risk of  lactic acidosis. Some 
small-scale studies have used metformin as an 
adjunctive therapy in overweight patients with 
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Improved glycemic control and insulin sensitiv-
ity as well as a decrease in daily insulin require-
ments without weight gain have been observed 
[354-359]. A newer class of  oral hypoglycemic 
agents, the thiazolidinediones, also called insulin 
sensitizers, improve glycemic control in patients 
with type 2 diabetes, and have a beneficial ef-
fect on microvascular complications beyond 
their effect on glycemic control [181]. To date, 
only a few studies have investigated the use of  
thiazolidinediones in patients with type 1 dia-
betes. One study used rosiglitazone to treat 50 
adult patients with type 1 diabetes and showed 
that the treatment was associated with a simi-
lar reduction in HbA1c and a similar increase in 
weight as in the control group. In the treatment 
group, this was achieved with a smaller daily in-
sulin dose, and the treatment further reduced 
blood pressure. The most pronounced effect 
of  rosiglitazone was seen in patients with signs 
of  insulin resistance [360]. By contrast, Zdravk-
ovic et al. showed no beneficial effect of  pio-
glitazone in 35 adolescents with type 1 diabetes. 
The treatment increased the body mass index, 
while a similar reduction in HbA1c was seen in 
both the intervention and control groups [361]. 
Larger studies are needed to assess the safety 
and efficacy of  both metformin and thiazolidin-
ediones in patients with type 1 diabetes. 
With the increasing epidemic of  obesity world-
wide, the presence of  the metabolic syndrome 
will certainly also increase in patients with type 
1 diabetes. This is a matter of  great concern 
since insulin resistance, the components of  the 
metabolic syndrome, and now also the metabol-
ic syndrome itself  are implicated in the patho-
genesis of  diabetic complications.
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Parental hypertension and type 1 diabetes, especially in the mothers, as well as paternal mor-I 
tality, particularly from cardiovascular disease, were independently associated with diabetic 
nephropathy in patients with type 1 diabetes. Parental type 2 diabetes and cardiovascular dis-
ease were not independently associated with diabetic nephropathy, but a cluster of  these two 
with parental hypertension was associated with diabetic nephropathy.
Parental history of  type 2 diabetes was associated with later onset of  type 1 diabetes, a meta-II 
bolic profile related to insulin resistance, and presence of  the metabolic syndrome in patients 
with type 1 diabetes, despite similar HLA genotype distributions. No association emerged 
between parental history of  type 2 diabetes and presence of  hypertension or diabetic compli-
cations in these patients. Maternal history of  type 2 diabetes seemed to be associated with a 
more unfavorable metabolic profile than paternal history of  type 2 diabetes. 
The metabolic syndrome was prevalent in patients with type 1 diabetes, being observed in III 
38% of  males and 40% of  females. The prevalence of  the metabolic syndrome increased with 
age, worsening of  glycemic control, and worsening of  renal disease. The metabolic syndrome 
was associated with 3.75-fold odds for diabetic nephropathy. The syndrome was further as-
sociated with a lower estimated glucose disposal rate, and a decline in insulin sensitivity was 
observed already in patients with microalbuminuria, well before apparent decline in renal 
function. This indicates that insulin resistance could precede the decline in renal function. 
The different definitions of  the metabolic syndrome, MSIV WHO, MSNCEP, and MSIDF, did not nec-
essarily identify the same patients. MSWHO, which includes microalbuminuria in the definition, 
was the best predictor of  cardiovascular morbidity and diabetes-related mortality, followed by 
MSNCEP, while MSIDF did not predict these outcomes. MSNCEP added to the risk of  cardiovascu-
lar morbidity, compared with albuminuria alone. Regarding the progression of  renal disease, 
MSWHO predicted progression to microalbuminuria, both MSWHO and MSNCEP predicted pro-
gression to end-stage renal disease, and MSIDF surprisingly seemed protective.
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